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ABSTRACT 
 
Complex regional pain syndrome type-I (CRPS-I) is a debilitating pain disorder often 
occurring secondary to distal extremity trauma. Its pathophysiology is not well 
understood; however, microvascular dysfunction is proposed as an important factor 
in its development and maintenance. Using a rodent model, we tested an automated 
gait analysis system (CatWalk™) to examine functional changes. In addition, the use 
of carbon monoxide releasing molecule-3 (CORM-3), a compound known to be a 
potent vasodilator and anti-inflammatory agent, was also tested as a treatment of 
CRPS-I-like symptoms. Using the CatWalk™ system, we observed significant 
changes in gait parameters post-injury, several of which persisted throughout the 14-
day experiment. CORM-3 administration significantly reduced mechanical allodynia 
symptoms, as demonstrated through the restoration of withdrawal thresholds during 
mechanical stimulation testing. Functional deficits were not restored after CORM-3 
application; however, trends for improvement were observed. CORM-3 has 
relevance as a potential therapy to alleviate symptoms associated with CRPS-I. 
 
Keywords: complex regional pain syndrome type-I, CORM-3, microcirculation, gait 
analysis, CatWalk™, carbon monoxide, chronic pain 
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CHAPTER 1:  INTRODUCTION AND HISTORICAL REVIEW 
1.1 COMPLEX REGIONAL PAIN SYNDROME 
 
In the clinic, persistent and chronic pain is the most common reason for 
patient presentation (Von Korff et al., 1988; Von Korff et al., 2008). Our current 
understanding of pain sensation and pain mechanisms in both normal and 
pathological conditions is continuously expanding and helping physicians to better 
cope with the increasing load of chronic pain patients. Headway has been made to 
recognize pain as a disease in its own right, as several studies show that over 1 in 5 
Canadians are affected by chronic pain. According to the Chronic Pain Association 
of Canada, “The cost of chronic pain for Canadians is well over 40 billion dollars in 
direct and indirect costs. This is more than cancer, HIV, and heart disease 
combined.” (Lynch, 2011) One such chronic pain condition, Complex Regional Pain 
Syndrome, has both significant direct and indirect costs on our society, and its 
peoples. 
Complex Regional Pain Syndrome (CRPS) describes a range of painful 
conditions and is characterized by a continuing regional pain – either spontaneous 
or induced – that is disproportionate to the inciting event or the usual course of a 
known trauma, in both time and degree. It typically occurs secondary to an extremity 
trauma and has a distal presence of abnormal sudomotor, vasomotor, sensory, 
motor and/or trophic signs (Bean et al., 2014; Bruehl et al., 2002; Harden, Bruehl, 
Perez, Birklein, Marinus, Maihofner, Lubenow, Buvanendran, Mackey, Graciosa, 
Mogilevski, Ramsden, Schlereth, et al., 2010). Typical symptoms include a constant 
burning pain, mechanical and cold allodynia, swelling, temperature changes and 
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limited active range of motion of the limb; exacerbation of symptoms is often 
observed upon exertion and exercise as well (M. Stanton-Hicks et al., 1998). Other 
considerable symptoms include severe motor dysfunction (dystonia, tremors, 
weakness, incoordination), dystrophy, psychiatric co-morbidities, sweating, bone 
changes, and changes in hair and nails. Anxiety and depression are common to this 
disorder, as patients often do not respond to any available treatment. Current 
therapeutic options include pharmacological, surgical, psychological and physical 
therapy (Harden, 2000; M. D. Stanton-Hicks et al., 2002). As a result of often failing 
treatment attempts, there is a push towards translational research in the study of 
CRPS. Although the triggers of the disorder are known (soft tissue injuries, fractures, 
sprains, crush injuries, surgery, spinal cord disorders and infections), CRPS 
sometimes occurs spontaneously, making it extremely difficult to diagnose (Wasner 
et al., 2001; Wilson et al., 2005). Diagnostic criteria are constantly evolving, as the 
consequences of a misdiagnosis can have multiple implications in patient quality-of-
life, employment status, and healthcare costs. As suggested by Harold Merskey’s 
quote below, pain is devastating to a person’s livelihood: 
“If I have matters right, the consequences of pain will include direct physical 
distress, unemployment, financial difficulties, marital disharmony, and 
difficulties in concentration and attention…” (Merskey, 2000). 
 
In order to help better understand the complex mechanisms underlying the 
pathophysiology of CRPS, and to develop accurate assessments for patients, both 
basic science and clinical research modalities are jointly needed. 
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1.2 HISTORY OF CRPS 
 
 
The history of CRPS traces back to 16th century European battles, where 
severe pain symptomology from trauma, induced by lance (and later, bullet) injuries, 
was reported (Bonica, 1953). Potts, a famous British surgeon, reported in the 18th 
century that trauma of the extremities can result in pain and atrophy (Hooshmand, 
1993). One of the first amputations was actually performed by a surgeon named 
Denmark on sailors whose musket bullet injuries resulted in severe burning pain with 
inflammatory symptoms; this condition was termed “tic douloureux” at the time (Ley, 
1835).  Throughout the next several hundred years, the nomenclature and definition 
of the disorder has seen many changes; however, no concrete description of the 
pathophysiology has been accepted.  
In the 19th century and the American Civil War, a physician named Wier 
Mitchell is accredited with describing the burning pain soldiers suffered from gunshot 
wounds and attributing it to a specific condition. He called the condition ‘causalgia’, a 
name originating from the greek word kausos for fever (from kaiein for “to burn”) 
(Mitchell, 1867). Together, Mitchell and William Keen (another doctor serving the 
Turner Lane Hospital in the Civil War) studied several nerve injuries, and eventually 
published “Gunshot Wounds and Other Injuries of the Nerves and Reflex Paralysis”, 
which described causalgia and secondary paralysis (Mitchell, 1864). In their 
publications, Mitchell, Keen and others described the severe burning pain, abnormal 
skin colour and temperature, sweating, muscle weakness, osteoporosis and 
involuntary movements that many soldiers experienced; effectively, well describing 
the disease (Mitchell, 1864, 1867). It wasn’t until 1916 that a proposal for the 
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mechanisms of causalgia was suggested by Leriche, who proposed that the 
sympathetic nervous system had an important role (Leriche, 1916).  
Suggesting a much different view on the source of pain, Paul Sudeck, a 
German physician, theorized that the bone atrophy and other symptoms observed 
were part of an inflammatory reaction after trauma. The syndrome was then referred 
to as Sudeck’s atrophy (Sudeck, 1902; van der Laan et al., 1998; Veldman et al., 
1993).  
William Livingston, an American surgeon during the Second World War, 
described a “vicious cycle” used to explain CRPS symptoms. The cycle explains 
how afferent input and reflex vasoconstriction could trigger pain, limb disuse and 
atrophy with even the most minor of nerve injuries (Livingston, 1948). From his 
hypothesis, Livingston performed many sympathectomies on suffering soldiers, 
some of which experiencing transient relief of pain symptoms. The findings resulted 
in Livingston suggesting an important role of the sympathetic nervous system in 
causalgia (Livingston, 1948).  
Around the same time Livingston was performing sympathectomies on injured 
soldiers, a surgeon by the name of Philip Foisie was hypothesizing the roles of 
arterial vasospasm and ischemia, from arterial and soft tissue injury, in causalgia 
(Foisie, 1947). Until then, vasospasms and ischemia had been largely ignored as 
potential factors contributing to CRPS. 
Formally called minor causalgia, the term “Reflex Sympathetic Dystrophy” 
(RSD) was introduced by John Evans in 1946, and referred to as causalgia without a 
visible major nerve injury (Evans, 1946, 1947). In 1986, the International Association 
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for the Study of Pain (IASP) defined RSD as “continuous pain in a portion of an 
extremity after trauma, which may include fracture but does not involve a major 
nerve, associated with sympathetic hyperactivity.” An additional definition, proposed 
by an Ad Hoc committee of the American Association of Hand Surgery, called RSD 
“a pain syndrome in which the pain is accompanied by loss of function and evidence 
of autonomic dysfunction.” However, in order to avoid any mechanistic term in its 
appellation, RSD had been renamed, as many cases did not seem to have 
sympathetically maintained pain, nor did result in dystrophy. Together, causalgia and 
RSD have had many different names describing them (Table 1.1). 
A discussion at the IASP Task Force on Taxonomy in 1994 resulted in a new 
umbrella term: Complex Regional Pain Syndrome (CRPS), which is now used 
instead, as there is “neither clinical nor pathological evidence to suggest that the 
mechanisms are any different in these two syndromes, and the responses (or lack 
thereof) to treatments are quite similar” (Wilson et al., 2005). Two types of CRPS are 
defined: CRPS-I, which encompasses what was formally RSD, and CRPS-II, which 
is what was formally known as causalgia. Type-I differs from type-II solely on the 
absence of a distinct nerve injury (Harden et al., 2007).  
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Table 1.1. Synonyms of Complex Regional Pain Syndrome 
 
Synonyms of Complex Regional Pain Syndrome 
Reflex sympathetic dystrophy (RSD) 
Causalgia 
Sudeck’s atrophy 
Post-traumatic dystrophy 
Shoulder-hand syndrome 
Algodystrophy 
Algoneurodystrophy 
Reflex neurovascular disease 
Pourfour du Petit syndrome 
Postinfractional sclerodactylia 
Fracture disease 
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1.3 DIAGNOSIS OF CRPS 
 
Sensitivity and accuracy of CRPS diagnosis is imperative to our health care 
system and patient quality of life. Being diagnosed with CRPS has serious 
implications to a patient’s ability to work and to maintain the livelihood of their 
families. A study by Kemler and Furnee (2002) concluded that the impact of chronic 
pain on both patients and their families could be unbearable physically and 
financially (Kemler & Furnee, 2002). They found that CRPS had a profound effect on 
employment status, time allocation, additional domestic help and out-of-pocket 
expenses (Kemler & Furnee, 2002). Therefore, early and accurate diagnosis and 
prompt management of symptoms are essential in reducing or preventing CRPS 
from worsening, as well as improving quality of life.  
 In Budapest, IASP consensus updated the diagnostic criteria for CRPS. 
Harden et al (2007) summarized the group’s revisions to the former diagnostic 
criteria, which aimed to reduce both over- and under-diagnosis of CRPS while 
maintaining diagnostic sensitivity (Harden et al., 2007). To make a CRPS diagnosis, 
the new criteria states that a patient must have: 
1. Presence of an initiating noxious event, or a cause of immobilization; 
2. Continuous pain, allodynia and/or hyperalgesia in which the pain is 
disproportionate to the inciting event; 
3. Evidence at some time of edema, changes in skin blood flow or abnormal 
sudomotor activity in the region of pain; 
4. This diagnosis is excluded by the existence of other conditions that would 
otherwise account for the degree of pain and dysfunction. 
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The diagnosis is further clarified if the patient is seen with or without major nerve 
damage. Nerve damage would result in a diagnosis of CRPS-II, whereas no nerve 
damage would garner a diagnosis of CRPS-I. The presence of an initiating noxious 
event may be unrequired as 5-10% of CRPS patients develop the syndrome 
spontaneously (Harden et al., 2007).  
 Considering that CRPS symptoms often vary slightly between patients and 
over time, probably as a result of a different contribution to symptoms from different 
pathophysiologic mechanisms, a clinical diagnosis has to meet several criteria. 
Clinicians examine four categories of symptoms: sensory (hyperesthesia and 
allodynia), vasomotor (temperature and skin colour changes), sudomotor/edema 
(edema and sweating changes and asymmetry), and motor/trophic (decreased 
range of motion; motor dysfunction like weakness, tremor and dystonia; trophic 
changes like hair, nail, and skin) (Harden et al., 2007). To make a clinical diagnosis 
of CRPS, the following criteria must be met: 
1. Continuing pain disproportionate to the inciting event; 
2. Patient reporting at least one symptom in at least three of the four categories 
listed above (sensory, vasomotor, sudomotor/edema and motor/trophic); 
3. Patient must display at least one sign in two or more of the above categories 
at the time of evaluation; 
4. No other diagnosis better explains the signs and symptoms. 
 
Clinically, the above criteria were agreed upon because, compared to the previous 
IASP diagnostic criteria, they limit false positives. However, depending on the 
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purpose for which the criteria are intended, the sensitivity and specificity of criteria 
might need adjusting. For example, in the research context, identifying stringent 
research samples by minimizing false positives is valuable, compared to clinically 
identifying as many CRPS cases as possible by minimizing false negatives (Harden 
et al., 2007). For this reason, diagnostic criteria in research are adjusted. In 
research, two of four sign categories and four of four symptoms categories must be 
positive for a CRPS diagnosis (Harden et al., 2007). These result in the greatest 
probability of CRPS vs non-CRPS according statistical analyses performed by 
Harden et al (2007). 
1.4 THERAPEUTIC APPROACHES AND MANAGEMENT 
 
 Over the last few decades, treatment plans for CRPS have adapted to new 
knowledge; however, the lack of consensus in the pathophysiology of the disorder 
have proved to make developing appropriate therapies very difficult, to say the least. 
Early recognition and treatment of CRPS-I are important because CRPS-I patients 
are at high risk of developing severe disability in the affected limb, potentially 
compromising future employment and livelihood (Poplawski et al., 1983).  
 Norman Harden presented a very good summary of why treatment of CRPS 
is inherently so difficult. It stated: 
 
“The syndrome is inherently complex biomedically, involving both peripheral 
and central pathophysiology, but it also often has psychosocial features that 
are critical diagnostic elements (and treatment targets). Successful treatment 
is further complicated by the diversity of patient presentation and by 
antecedent pathology. In addition to these clinical challenges, the 
epidemiology and natural history of CRPS are poorly understood. Even 
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research data are challenging to interpret, and evidence has been slow to 
accumulate as to how best to treat CRPS, due in large part to the vagaries of 
diagnosis (see Chapter 4). How is a specialist to begin treating such a 
multifaceted condition?” (Wilson et al., 2005) 
 
 Indeed, how is a specialist to begin treating such a multifaceted condition? 
This question was address by Harden and others in CRPS: Current Diagnosis and 
Therapy in 2005, after an IASP conference in Budapest. The authors also presented 
a general treatment algorithm, suggesting an interdisciplinary method for handling 
CRPS, with a focus on functional restoration. This algorithm recommends the use of 
conservative care, via physical/occupational therapy and oral medications, when a 
patient continues to have persistent pain or dysfunction. With regular consultation, if 
a patient continues to experience CRPS symptoms with conservative care, 
intermittent regional nerve blocks are then sometimes prescribed. If a failure to 
progress from nerve blocks were observed, a move to infusion techniques (i.e 
epidural infusions) would be recommended. If CRPS symptoms persist, the patient 
may be a candidate for spinal cord stimulator implantation or intrathecal drug 
delivery. These options are more invasive and should only be considered if other 
therapies fail; additionally, the authors suggest intrathecal drug delivery should only 
be considered if spinal cord stimulation fails to relieve symptoms, or if a patient 
exhibits a plateau of response (Wilson et al., 2005). Such treatments will be 
discussed further in the following sections. Of course, CRPS is a very complex 
condition and treatments cannot be expected to be identical between patients. The 
basic principle of the functional restoration guidelines is to identify progress through 
the steps of care, and to intervene with additional treatments if patients do not 
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progress (Wilson et al., 2005). Treatment guidelines emphasize using a multi-
disciplinary approach, to compassionately and methodically help patients regain 
their quality of life. 
 The development of additional treatments, targeting potential mechanisms 
explaining the initiation and maintenance of CRPS, are needed. Patients are often 
frustrated by the lack of relief pain management regimens provide; the development 
of adjunct therapies may help both clinic and patient relieve pain and frustration. 
 
1.4.1 Rehabilitation Therapy 
 
 In keeping with the focus on functional restoration, rehabilitation therapy is an 
important part in CRPS treatment. Until recently, rehabilitation has been stated as 
vital, or at least a supportive complementary approach to CRPS; however, its 
techniques, frequency and intensity are rarely described in the literature. Instead, 
writings tend to focus on explanatory hypotheses, medical interventions and 
adjustments to diagnostic criteria. 
 Rehabilitation is the culmination of both physical and occupational therapy, 
with the aim of focusing treatments on the clinical manifestations of CRPS, including 
edema, restricted range of motion, temperature sensitivity, intolerance of physical 
activity, reduced muscle strength and, of course, pain. Although physical and 
occupational therapists differ in their scope of practice, much of their work overlaps 
in the treatment of a chronic pain syndrome (Wilson et al., 2005).  
 In the treatment of CRPS, the first steps are often to manage edema and 
pain. The next goal is the initiation of gentle, active movements, to restore range of 
	  	  
13 
motion. Finally, improvement of muscle strength and function of the extremity are 
targeted to fulfill the end goal of improving whole body function, to allow patients to 
be participating members of society (Bengtson, 1997). In a prospective randomized 
control trial that followed patients over the course of 1 year, physical and 
occupational therapy modalities led to recovery from CRPS of the upper extremity 
(Oerlemans et al., 1999). 
Reducing edema is often achieved through lymph draining and by active 
exercises; however, a study by Uher et al (2000) observed no difference between 
active exercises and active exercises plus lymph draining. This would suggest that 
physical therapy may be more effective in reducing edema (Uher et al., 2000).  
 Providing a balanced and varied approach to managing symptoms, physical 
and occupational therapy as part of the rehabilitation method is currently the pivotal 
intervention for CRPS, as determined by several large consensus meetings (Harden, 
Bruehl, Perez, Birklein, Marinus, Maihofner, Lubenow, Buvanendran, Mackey, 
Graciosa, Mogilevski, Ramsden, Chont, et al., 2010; Harden et al., 2007). As 
confirmed in rat models, normalization of function may serve to reverse changes 
observed in CRPS patients (Guo et al., 2004).  
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1.4.2 Medications and Pharmacotherapy 
 As a result of a lack of efficacy of rehabilitation therapy for CRPS patients, 
pharmacotherapy often becomes the major treatment option for those patients 
whose symptoms do not improve. Of course, used in conjunction with other 
therapies as directed by pain specialists, medications are prescribed for both early 
and chronic CRPS, as well as chronic CRPS symptoms other than pain.  
 Since CRPS is often initiated by trauma or injury, most studies examining 
treatments and therapeutic approaches have been performed by surgeons, 
orthopaedists or rehabilitation specialists. As stated previously, acute CRPS is 
characterized by pain and inflammation; however, it’s believed that the final effects 
on the central nervous system may not have occurred yet, leaving an important 
window for treatments to potentially affect the disease course (Wilson et al., 2005).  
The mechanisms and targets of treatment are probably different in acute and chronic 
CRPS, and there are very few studies investigating the effectiveness of early CRPS 
treatments on chronic CRPS patient symptoms. 
 Some evidence-base studies have found that treatments prescribed in early 
CRPS include: corticosteroids, calcium-regulating drugs, alpha-adrenergic 
antagonists, and anti-oxidants. A study by Christensen et al (1982) found that 
systemic corticosteroid (prednisone) treatment reduced entire clinical status by more 
than 75%; however, corticosteroids are typically not administered in chronic CPRS 
patients (>6 months) as it has little efficacy (Christensen et al., 1982). Prednisone 
and methylprednisolone are agents with anti-inflammatory properties, probably 
affecting neurogenic inflammation and subsequently pain symptoms.  
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Calcium-regulating drugs like clodronate and alendronate, as well as the 
hormone calcitonin, have been found to improve swelling, pain, and range of motion 
in several randomised clinical trials (RCTs) (Braga, 1994; Manicourt et al., 2004; 
Perez et al., 2001; Varenna et al., 2000; Zyluk, 1998). The mode of action of these 
treatments is not clear. 
 Considering the hypothesis that CRPS is caused by oxygen-derived free 
radical damage that potentiates inflammation and microvascular dysfunction, several 
studies have investigated antioxidants and free-radical scavengers as possible 
therapeutics. One such study found that topical dimethylsulfoxide (DMSO) provided 
alleviating effects (Zuurmond & Perez, 2006); however, a strong garlic odour in 
exhaled breath was observed as an adverse effect. 
 Alpha-adrenergic antagonists and vasodilators have also been examined in 
CRPS patients; although two studies show potential benefits of the alpha-adrenergic 
antagonist phenoxybenzamine in both early and chronic CRPS (Ghostine et al., 
1984; Muizelaar et al., 1997), adverse effects of hypotension from vasodilatory 
action are very serious. 
 In Table 1.2 below, the major classes of medications, with documented 
efficacy, used in the treatment of chronic pain are summarised. Bearing in mind the 
wide range in CPRS symptom presentation, no single medication is better or worse 
than others, so clinicians must consider patient symptoms, age, circumstances and 
personal history when prescribing medications. 
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Table 1.2. Major Classes of Medications Used in Treating Chronic Neuropathic 
Pain 
 
 
 
 
 
Treatment 
 
Medication Name 
Topical local anesthetics 
• Lidocaine 5% patch 
• Local anesthetic cream, gel, ointment 
Tricyclics 
• Nortiptyline 
• Desipramine 
Antiepileptics 
• Gabapentin 
• Carbamazepine (extended release) 
Opiods 
• Tramadol 
• Oxycodone (extended release) 
• Morphine (extended release) 
• Methadone 
 
Adapted from Wilson et al 2005 (Wilson et al., 2005)  
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 With minimal complications to its use, local anesthetics have active 
ingredients that act locally at the site of application, typically the affected extremity 
(Wilson et al., 2005). These agents differ from other transdermal medications like 
fentanyl, which have a systemic distribution once absorbed across the skin. Gels, 
creams, sprays and patches with active anesthetic ingredients (like lidocaine) are 
supported by level 2 evidence for relief of allodynia symptoms in CRPS. The 5% 
lidocaine patch is especially popular since it both covers the skin from potential 
contact and has active anesthetic to relieve allodynia symptoms (Wilson et al., 
2005). 
 Tricyclics, or tricyclic antidepressents (TCAs), are perhaps the most beneficial 
pharmacological CRPS therapy in use today (Jensen, 2002). Several trials have 
found TCAs to be effective in reducing neuropathic pain (Jensen, 2002; Max et al., 
1987; Max et al., 1992; Raja et al., 1992; C. P. Watson et al., 1992). They also 
happen to be one of the most inexpensive therapeutic options, as generic forms of 
the agent are available. To decrease CRPS symptoms, TCA acts on several 
mechanisms to alter noradrenergic inhibitory pathways for decreased dorsal horn 
hyperactivity as well as the depression and psychological changes that accompany 
the disorder. Use in the elderly is discouraged, however, since some TCAs (such as 
amitriptyline) may contribute to cardiac arrhythmias.  
 Currently FDA-approved for use in epilepsy and post-herpetic neuralgia 
(PHN), some antiepileptic drugs also exhibit antihyperalgesic properties, by 
decreasing central neuronal hyperexcitability (Wilson et al., 2005). Gabapentin, the 
best-studied antiepileptic, has been deemed efficacious and safe for CRPS patients 
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after a study giving patients 600 mg/day (Mellick & Mellick, 1997). Its action is 
thought to be the binding of alpha-2-delta subunit of voltage-gated calcium channels 
for the decrease of synthesis and release of excitatory neurotransmitters (Gee et al., 
1996). Compared with TCAs, gabapentin has no drug-drug interactions and no 
serious adverse effects; however, other anticonvulsants and antiepileptics have 
inconclusive evidence as to their efficacy in pain disorders like CRPS. 
 The last major class of medication used in the treatment of CRPS patients is 
the opioid medications. Reluctance to prescribe opioids is common amongst 
practitioners for several reasons, including a potential for severe substance abuse 
and addiction, evidence for the cause of diffuse pathological hyperalgesia after long-
term opioid use, and physical tolerance at certain doses (applicable to other 
medications as well) (Wilson et al., 2005). Although there are several consequences 
of opioid use to consider before prescribing, there is abundant level 2 support for the 
use of opioids in other painful conditions, including PHN and painful diabetic 
neuropathy (PDN). Similar to TCAs, opioids do not cause any cognitive deficits as 
detected by neuropsychological testing (Wilson et al., 2005). One study by Watson 
and Babul (1998) found that controlled-release oxycodone at 60 mg/day contributed 
to a 35% reduction in pain in PHN (C. P. Watson & Babul, 1998); other studies show 
oxycodone ability to reduce pain by 30% in PDN as well (Gimbel et al., 2003; C. P. 
Watson & Babul, 1998; C. P. Watson et al., 2003). Tramadol is an opioid suggested 
to have similar effects in both PDN and other painful neuropathies (Sindrup et al., 
1999). The data for use in CRPS is inadequate as there are limited RCTs with solid 
conclusions; however, opioid treatment is currently prescribed.  
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Thus, pharmacotherapy can reduce symptoms of CRPS; however, there are 
several drawbacks to the indefinite use of medications: in most patients, only a 
temporary or partial relief from symptoms is provided, unable to “cure” CRPS. Other 
treatments (e.g. electrical stimulation) have been found to have disease-modifying 
effects, such as persistent pain relief even after treatment is complete (Wilson et al., 
2005). Another limitation is the length of therapy; the median age of CRPS is 
approximately 40 years (Wilson et al., 2005), thus these patients may potentially 
need to take prescription medications for decades. Not only are the long-term effects 
of prolonged medication use generally unknown, but the long-term use may have 
significant impacts on social, economic, and medical aspects of patient livelihood.  
 Currently, much of the evidence-based pharmacotherapy comes from data 
extrapolated from RCTs for other diseases. Therefore, further work investigating 
potential disease-modifying or protective agents, as well as performing RCTs 
specific to CRPS patients, is needed.  
1.4.3 Injection Therapy	  
   
Traditional interventional therapies also include symptom relief though 
injection of various compounds. CRPS was formally named reflex sympathetic 
dystrophy for the implied mechanistic involvement of the sympathetic nervous 
system; this belief led to various treatments aimed at sympathetic blockade. 
Although there is indeed sympathetic nervous system involvement (i.e 
sympathetically-maintained pain (SMP)), CRPS is a complex disease where 
sympathetic blockade does not always provide relief. Sympathetic nerve block does, 
however, provide insight into the diagnosis of pain in CRPS patients as either SIP or 
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SMP. Common blocks include: sympathetic nerve blocks, intravenous regional 
anesthesia (IVRA), intravenous infusions and others.  
 Depending on the location of symptoms, sympathetic nerve blocks are 
traditionally delivered at the level of stellate ganglion or lumbar sympathetic chain 
(Wilson et al., 2005). Sometimes, pain relief is evident even after the effects of local 
anesthesia have expired; in some cases, pain relief may be long-lasting (Burton & 
Waddell, 1998; Price et al., 1998). In 2002, a systematic review by Cepeda and 
colleagues of over 79 reports on sympathetic blockade found that most reports had 
to be rejected as CRPS diagnostic criteria has evolved markedly in the last 100 
years (Cepeda et al., 2002). After pooling the data from only 29 remaining studies, 
Cepeda and colleagues found that only 17% of 454 patients had partial or complete 
pain relief; the duration of pain relief varied significantly and Cepeda also concluded 
that it may be inaccurate to pool much of this data together. Overall, there is some 
evidence for the benefit of classic sympathetic nerve blocks; however, they still 
remain in most treatment plans as either a test to differentiate SMP from SIP, or to 
help supplement active rehabilitation/physical therapy regimens.  
 IVRA is a fairly simple technique used to relieve pain symptoms by delivering 
anesthetic directly to the affected limb. This is performed by injecting an anesthetic 
compound, or a mixture of several compounds, into the circulation of the affected 
limb, while isolating the limb from the rest of circulation with a tight-fitted tourniquet 
(Davis et al., 2002). The likely mechanism for the block of sympathetic nerves is 
through vascular beds around peripheral nerves, the vasa nervorum and valveless 
venules around nerve endings (Wilson et al., 2005); diffusion of the local anesthetic 
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into local tissues may also be involved. Several high-quality studies have been 
published comparing local anesthetics delivered by IVRA including guanethidine, 
lidocaine, bretylium, clonidine, droperidol, ketanserin and reserpine (Forouzanfar et 
al., 2002; Kingery, 1997; Perez et al., 2001). 
 Intravenous infusions of phentolamine and lidocaine have also been studied 
for the relief of pain symptoms. Intravenous infusion involves the controlled injection 
of fluid into the circulatory system by an infusion pump. Studies differ on the effect of 
phentolamine; a study by Arner et al (1991) reported an analgesic effect in both 
adults and children with CRSP-I and II, but Verdugo and Ochoa (1994) found that 
neither placebo nor phentolamine provided any changes in pain, blood flow or 
sensory testing after a prospective, single-blinded study (Arner, 1991; Verdugo & 
Ochoa, 1994). Intravenous infusions are not used as much recently and when used, 
they often act as a diagnostic tool to differentiate SIP and SMP. 
 
1.4.4 Psychological Interventions 
Similar to several other chronic pain disorders, CRPS is a complicated 
biopsychosocial disorder that requires multidisciplinary treatment in order to improve 
psychological, social and medical aspects of patient health. Currently, there are very 
limited controlled studies examining the efficacy of different types of psychological 
intervention; however, there are several approaches that have shown benefit. These 
include relaxation training, biofeedback, cognitive intervention and hypnotic imagery 
(Wilson et al., 2005). As part of a multidisciplinary treatment package, many of the 
above approaches have yielded significant alleviation of CRPS symptoms. A RCT by 
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Oerlemans et al (1999 and 2000) of 135 adult CRPS patients concluded that 
relaxation training and cognitive interventions in conjunction with physical therapy 
yields a significantly greater improvement in CRPS symptoms than controls at a 
one-year follow up (Oerlemans et al., 1999; Oerlemans et al., 2000). Several case 
studies have shown almost complete resolution of symptoms after biofeedback 
(muscular and thermal), relaxation training and hypnotic imagery (Barowsky et al., 
1987; Blanchard, 1979; Gainer, 1992). These approaches often target the learned 
limb disuse that patients develop. Clinical experiences suggest that using the above 
techniques in an integrated multidisciplinary context can provide substantial relief of 
symptoms. 
1.4.5 Implanted Therapies 
 
 In addition to traditional interventional therapies, advanced pain medicine 
techniques used in the treatment of CRPS include spinal cord stimulation (SCS), 
peripheral nerve stimulation (PNS), and intrathecal drug delivery (ITDD). These 
implantable modalities are more commonly used for CRPS conditions that do not 
respond appropriately to pharmacotherapy, regional nerve blocks or physical 
therapy. 
 
1.4.5.1 Spinal Cord Stimulation 
 Nerve stimulation (either spinal cord or peripheral nerve) was first suggested 
for use in pain in 1967 (Shealy, Mortimer, et al., 1967; Shealy, Taslitz, et al., 1967). 
SCS was performed by Cook et al (1976) for pain relief of secondary ischemia to 
peripheral vascular disease (Cook et al., 1976). It was also found to improve 
	  	  
23 
perfusion after Jacobs et al (1988) showed relief of ischemic leg pain and 
improvement of ulcer healing (Jacobs et al., 1988). SCS is performed by the 
implantation (either temporary or permanent) of small, soft wires near the spinal 
cord. These wires have electrical leads on their tips that pass electrical currents that 
are produced by a small programmable generator often surgically placed under the 
skin of the buttocks or abdomen. Neurostimulation in this manner blocks pain signals 
by applying a mild electrical current to the spinal cord (SC), often resulting in less 
pain and a tingling feeling in the affected area called paresthesia (Wilson et al., 
2005); however, the exact mechanisms by which SCS relieves pain is still not fully 
understood. It was originally though to target the dorsal column of the SC but other 
studies showed that neurostimulation also influenced transmission (affecting sensory 
dorsal nerves and descending inhibitory pathways in the SC) (Linderoth et al., 1992; 
Long et al., 1981). It is also thought that the improved peripheral circulation after SC 
stimulation is the result of autonomic effects as the neurostimulation may modulate 
efferent impulses that could produce vasodilation in the innervated dermatome 
(Wilson et al., 2005). 
 
1.4.5.2 Peripheral Nerve Stimulation (PNS) 
 PNS works in a similar manner to SCS:,small electrodes are placed along 
peripheral nerves in the targeted limb and often cause a reduction in pain, as well as 
the same paresthesia observed in SCS (Wilson et al., 2005). PNS can be used 
alone, but it is often used together with SCS. An indication for this type of treatment 
is pain predominating in a region innervated by only one peripheral nerve. In both 
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SCS and PNS, nerve stimulation is temporarily tested to allow for patient feedback 
before any permanent surgical implant is in place (Wilson et al., 2005). Although 
there are limited randomized studies examining this treatment, pain relief has been 
demonstrated in several retrospective studies (Ebel et al., 2000; Law et al., 1980). 
 
1.4.5.3 Intrathecal Drug Delivery 
	  
 ITDD is a complex technique involving the implantation of infusion pumps that 
deliver pharmacological agents directly to a site on the spinal cord (Wilson et al., 
2005). The intrathecal pump, sometimes called the “pain pump”, has been typically 
used for patients with cancer pain (Onofrio et al., 1981); however, CRPS patients in 
several case studies have found pain relief from this technique. Medication is 
delivered via small catheters that originate in a small pump surgically implanted 
under the skin of the abdomen (Institute, 2013). Typically, morphine is the first-line 
agent used in ITDD. Morphine administered via intrathecal pump has been reported 
effective several times, especially in severe cases of CRPS.  
There are limitations to ITDD. Similar to other opioid treatments, dose 
increases are usually required. Complications with the catheter tip exist, where tip 
masses can form when medication is delivered at high concentration (McMillan et 
al., 2003). Finally, kinking of the catheter often causes a mild red rash on the skin 
and jeopardizes the integrity of the catheter (Wilson et al., 2005).  
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1.4.6 Other Therapeutic Approaches 
 
 Several techniques are either not approved or have limited evidence to 
support their use; a sample of these approaches are briefly addressed in this section 
below. 
In consideration of the tissue hypoxia and acidosis that often accompanies 
CRPS, Kiralp et al, Tuter et al and Peach all proposed the use of hyperbaric oxygen 
(HBO) therapy (Kiralp et al., 2004; Peach, 1995; Tuter et al., 1997). In a randomized, 
placebo-controlled study, Kiralp demonstrated the use of HBO therapy in markedly 
attenuating edema and pain in CRPS patients after 15 treatments; these findings 
lend additional support to warrant further research of HBO therapy and for 
treatments targeting edema and hypoxia for pain relief.  
 Traditional Chinese medicine involves qigong, a concept with growing 
popularity in North America that focuses on balancing one’s “life energy”. Recently, 
its use has been examined for therapeutic benefits in many conditions ranging from 
cancer and pain, to obesity and hypertension (Bao et al., 2014; Elder et al., 2007; 
Xiong et al., 2015). Although there are some clinical studies suggesting qigong as a 
potential treatment for CRPS-I (Lee et al., 2007; W. H. Wu et al., 1999), the small 
number of participants involved precludes any solid conclusion. Further research 
may be warranted for its use in resolving depression, anxiety and other psychiatric 
complications resulting from CRPS diagnosis. 
 One event known to trigger CRPS complications is surgery. Casting and 
tourniquet use have been suggested as possible initiating noxious events for CRPS. 
A preventative, rather than therapeutic, approach to CRPS has been studied for 
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surgical cases by using vitamin C. One-gram daily of vitamin C treatment was found 
to be effective at preventing CRPS after both upper and lower limb surgery (Besse 
et al., 2009; Zollinger et al., 1999). More recently, Vitamin C was found to have an 
antiallodynic effect in rats, when delivered once per day for 3 days before a hindpaw 
ischemia-reperfusion injury was induced (the chronic post-ischemia pain model 
(CPIP) (Park et al., 2013). Co-administration with vitamin E had a greater 
antiallodynic effect in the experiment, and together these vitamins were suggested 
as modulators of spinal cord neuropathic pain processing. 
 A relatively radical approach to CRPS is a ketamine coma, where extended 
use of anesthetic dosages of ketamine is used to place a CRPS patient in a coma. 
Ketamine has been found to reduce pain significantly is many patients when applied 
topically or by IV; however, the ketamine coma has been suggested to reset NMDA 
receptors and block the central sensitization existing in CRPS (Henson & Bruehl, 
2010). Studies examining its use are limited and the treatment is still considered 
controversial and unproven in Canada. 
 A common theme in the discussion of most therapeutic approaches for CRPS 
is that further study is required. Many studies lack quality controls or a large sample 
size to confidently state conclusions. Clinical trials on both CRPS patients and those 
at risk of developing CRPS (e.g., receiving knee replacement surgery) is to assess 
the efficacy of various treatments and to better understand the best multi-disciplinary 
approach to treating CRPS. 
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1.5 PATHOPHYSIOLOGY  
 
 Current knowledge of the pathophysiologic mechanisms driving CRPS 
symptoms suggests they are multifactorial. A recent comprehensive review by 
Bruehl (2010) presents a summary of the most widely accepted and documented 
pathophysiologic mechanisms that may contribute to CRPS; they include peripheral 
and central nervous system sensitization, inflammation (increased pro-inflammatory 
cytokines and decreased anti-inflammatory cytokines), altered sympathetic and 
catecholaminergic function, altered somatosensory representation in the brain, 
genetic factors and psychophysiologic interactions (Bruehl, 2010). It is now clear that 
the above multiple mechanisms are involved, and that CRPS presentation depends 
on the relative contribution of each mechanism. 
 The majority of CRPS patients have a clinical history of some noxious injury 
(trauma, ischemia, nerve injury) that initiates their symptoms. Often, as a result, 
clinicians observe signs of inflammation (e.g. edema, redness and hyperemia). 
Increased local and systemic levels of pro-inflammatory cytokines (e.g. TNF-alpha, 
IL-1beta, IL-2 and IL-6) have been observed and correlated with CRPS symptoms in 
patients (Maihofner et al., 2005; Uceyler et al., 2007). Decreased anti-inflammatory 
cytokines (e.g. IL-10) are observed in CRPS patients as well (Uceyler et al., 2007). 
Pro-inflammatory cytokines are released after trauma by classical inflammatory 
mechanisms, by action of immune cells (lymphocytes, mast cells, etc); the effect of 
is plasma extravasation, and subsequently edema, which probably explains the 
edema and swelling often observed in CRPS patients. In addition to pro-
inflammatory cytokines, neuropeptides Substance P and calcitonin gene-related 
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peptide (CGRP) can trigger neurogenic inflammation (Bruehl, 2010). Neuropeptides 
and pro-inflammatory cytokines have also been found to produce peripheral nerve 
sensitization, leading to increased nociception (Bruehl, 2010). These molecules 
have also been found to stimulate osteoclasts, explaining the osteoporosis 
frequently observed in CRPS patients (Birklein & Schmelz, 2008). 
 Sensitization of peripheral nerves, which leads to persistent pain, is triggered 
by the initial tissue trauma and inflammation as explained above and is present early 
in CRPS symptomatology. After trauma, release of neuropeptides and inflammatory 
cytokines can increase background firing of nociceptors and decrease the firing 
threshold for mechanical and thermal stimuli, resulting in allodynia and hyperalgesia 
observed in CRPS patients (Bruehl, 2010; J. Cheng & Ji, 2008; Couture, 2001). 
Central sensitization is the increased excitability of nociceptive neurons in the spinal 
cord, often resulting from persistent noxious input after tissue damage or nerve 
injury (Bruehl, 2010). Sensitization of the central nociceptors is often controlled 
through neuropeptides and at N-methyl-D-aspartate (NMDA) receptors, leading to 
extremely amplified responses to noxious stimuli (hyperalgesia) as well as to non-
painful stimuli (allodynia) (Bruehl, 2010; Gracely, 1992; Gracely et al., 1992).  
 Reduced cutaneous innervation of the affected limb has also been observed 
in CRPS patients. Although CRPS-I has no clinical signs of nerve injury, Albrecht 
and colleagues observed a reduced density of nerve fibres (both C- and A-delta 
fibres) in the affect limbs of CRPS-I patients (Albrecht et al., 2006). No causative 
role in the development of further CRPS symptoms has been proven; however, 
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needle stick injury in rodents to distal nerves has resulted in the development of 
similar symptoms to CRPS-I patients (Albrecht et al., 2006; Siegel et al., 2007b).  
 Altered sympathetic nervous system (SNS) function has historically been 
linked to CRPS, as classical symptoms include ‘cool’ and ‘blue’ affected limbs, 
caused by vasoconstriction from SNS outflow. It is believed that pain in some CRPS 
cases is sympathetically maintained, meaning that there is excessive SNS outflow 
that results in pain. Sympathetic nerve blocks as a treatment option directly arose 
from this ideology. Studies in rodents have found that increased adrenergic 
receptors are expressed on nociceptive nerve fibres after trauma, perhaps 
explaining why nociceptive signals are triggered (Janig & Baron, 2002). The receptor 
expression may be linked to sympatho-afferent coupling, which results in 
sympathetic nerve activity stimulating these receptors on nociceptive fibres. Afferent 
nociceptive fibres become sensitized to adrenergic excitation, leading to increased 
firing in the presence of sympathetic outflow or circulating catecholamines. (Arnold & 
Delbos, 2003; Baron & Maier, 1996; Harden et al., 1994; H. A. Kurvers, 1998). The 
persistent activation leads to sensitization of the central nervous system as well.  
 Hypofunction of the SNS directly after injury is believed to upregulate the 
expression of peripheral catecholaminergic receptors, resulting in supersensitivity to 
circulating catecholamines, causing vasoconstriction (Birklein et al., 1998; Harden et 
al., 1994; H. Kurvers et al., 1998). Despite a lower level of catecholamines in the 
affected limb of CRPS patients, vasoconstriction is observed; this is probably the 
result of sensitization of peripheral adrenergic receptors during the acute phase of 
CRPS (Bruehl, 2010). Therefore, vasoconstriction may still occur even with 
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decreased local sympathetic outflow. The sensitization of adrenergic receptors also 
explains the exaggerated sweating and vasoconstriction observed after exposure to 
circulating catecholamines. Catecholamines can increase in the event of regular life 
stress or pain sensations. An odd vicious cycle may occur where catecholamine 
release leads to nociceptive input, maintaining an altered central process that 
generates more pain, and subsequently more catecholamine release (Wilson et al., 
2005). 
 There are limited studies examining CRPS using imaging techniques, 
however one review of neuroimaging literature has concluded that there is little 
evidence supporting the concept of a “pain network” in neuropathic pain syndromes 
(Moisset & Bouhassira, 2007). After acute pain experiments, researchers have been 
able to correlate activity in specific areas of the brain with various experimental 
stimuli inducing pain; however, brain activity as a result of clinical pain, more 
specifically chronic pain, is not well understood and does not correlate well with the 
“pain network” or “pain matrix” characterized after inducing experimental pain. Also, 
there is no evidence for a consistent brain activation pattern associated with 
allodynia. All of this considered, there have been several studies of CRPS using 
neuroimaging techniques that observe one consistent brain alteration: a 
reorganization of the somatotopic map. More specifically, the alteration is a 
reduction in the size of the representation of the affected limb in the somatosensory 
cortex (Juottonen et al., 2002; Maihofner et al., 2003). The degree of this brain 
plasticity has been directly correlated to the level of hyperalgesia, as well as CRPS 
pain intensity (Bruehl, 2010; Maihofner et al., 2003). Somatotopic reorganization in 
	  	  
31 
CRPS patients has also been linked to impaired sensory perception, like the ability 
to discriminate between two-point tactile stimulation. Although it is not known when 
in CRPS development the reduced limb representation occurs in the brain, these 
findings have clinical importance and reflect the multifaceted nature of CRPS. 
 Genetic factors have been suggested to play a role in CRPS. Small sample 
studies have correlated CRPS development with a familial link. Onset of CRPS in 
siblings of CRPS patients occurs 3-times as often as non-familial cases (de Rooij et 
al., 2009). Genes involved with major histocompatibility complex encoding the 
human leukocyte antigen (HLA) molecule, and genes involved in inflammation (like a 
TNF-alpha promoter gene) have been thought to play a role in CRPS development 
(Vaneker et al., 2005). A polymorphism of the TNF-alpha promoter gene has been 
suggested to increase TNF-alpha levels, perhaps contributing to the exaggerated 
inflammatory response observed in CRPS patients. The hypothesis that genetic 
factors play a role in CRPS development is still being assessed, and no study has 
provided evidence from a large sample size to link the two. 
 A psychological cause for the development of CRPS has been hypothesized 
since the syndrome was formally recognized; today, some still continue to hold this 
idea (Ochoa & Verdugo, 1995). The literature currently holds very few strong 
prospective studies examining this hypothesis, although theoretically it is possible 
that psychophysiological mechanisms may contribute to the development of CRPS 
(Bruehl, 2010). However, psychogenic factors alone are not sufficient to produce the 
signs of CRPS. One study by Harden et al (2003) found that higher anxiety levels 
before total knee arthroplasty surgery were associated with a greater likelihood of 
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being diagnosed with CRPS by 1-month post-procedure (Harden et al., 2003). This 
may be related to the increase in catecholamine activity observed during 
psychological distress (Charney et al., 1990; Harden et al., 2004), potentially 
contributing to the adrenergic mechanisms involved in CRPS (Bruehl, 2010). 
Although there are theoretical links and a few prospective studies that suggest 
psychological factors impact on the development of CRPS, further prospective work 
is required to provide any empirical evidence.  
 No empirical studies have been performed evaluating the interactions 
between many of the pathophysiological mechanisms described above; however, 
Bruehl (2010) described a speculative model of how these mechanisms may come 
together in CRPS development and maintenance (Bruehl, 2010). His model is 
illustrated in Figure 1.1. CRPS is clearly multifaceted in its pathophysiologic 
mechanisms, and further studies are required to comprehensively evaluate the 
contribution of each mechanism to CRPS signs and symptoms. Considering that 
mechanism-based treatment is a goal in CRPS therapy, our lack of understanding 
the pathophysiology is detrimental not only to patients and the healthcare system, 
but arguably also to our economy, since many CRPS patients are unable to work. 
Further research into identifying pathophysiologic mechanisms may eventually 
permit the development of effective clinical treatment options and, perhaps, a “cure”.  
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Figure 1.1. Speculative contributions of pathophysiologic mechanisms in CRPS 
 
  Adapted from Bruehl 2010. 
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1.6 ANIMAL MODELS OF CRPS-I 
  
Limited in number, there have been several attempts to model CRPS-I in 
small animals. Compared with CRPS-II animal models, which have been well 
characterized through the use of nerve injury, the key to developing a CRPS-I 
animal model has been the induction of neuropathic-like pain without initiating a 
major nerve injury. 
 One of the first animal models describing CRPS-I symptomatology was 
developed by van der Laan et al (van der Laan et al., 1997). It involved the 
administration of a free-radical donor called tert-butyl-hyperperoxide into the femoral 
artery of conscious rats for 24 hours. The result was mechanical allodynia, lasting for 
at least 4 weeks. The authors hypothesized that free-radical application triggered a 
sensitization of both peripheral nerves and central processing and subsequently, the 
hyperalgesia and allodynia (van der Laan et al., 1997). Plasma extravasation and 
significant inflammatory signs (redness, increased temperature and edema) were 
also observed. After treatment with a free-radical scavenger before and after injury, 
the authors found significantly altered effects. While this model presented a very 
interesting attempt at modelling CRPS-I, no further studies have been done. 
 Another model, developed in 1998 by Vatine et al, used electrical stimulation 
of the sciatic nerve to initiate hyperalgesia and allodynia (Vatine et al., 1998). The 
authors applied a 0.5 Hz and 8mA electrical stimulation to the sciatic nerve 
supramaximally for 10 minutes and found that animals developed significant thermal 
hyperalgesia, as well as some cold and mechanical allodynia symptoms. They 
hypothesized that sensory changes were due to sensitization of the nerve or its 
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central connections, and not a nerve injury. Symptoms normally observed in CRPS-I 
patients, like swelling, redness and dystrophy, were not observed, thus no follow-up 
studies were conducted. 
 Inducing signs of mechanical allodynia, ischemia and inflammation, Gradl et 
al (2005) developed a CRPS-I animal model initiated by a controlled-impact soft-
tissue injury and intra-arterial infusion of inflammatory mediators (Gradl et al., 2005). 
The authors found that mechanical allodynia and local inflammatory effects were 
triggered after intra-arterial infusion of Substance P for 24 hours. This model 
presents an interesting method for initiating CRPS-I-like symptoms; however, 
behavioural observations were only followed for four days post-injury and there was 
no evidence of hyperalgesia or spontaneous pain behaviours. 
A study by Oaklander et al (2006) showed evidence for minor nerve injury in 
CRPS-I patients, suggesting that minor nerve injury may induce CRPS 
symptomatology (Oaklander et al., 2006). Complementing these findings, Siegel et 
al (2007) developed a novel model of CRPS-I by initiating a minor nerve injury of the 
tibial or sural nerve using needle puncture (Siegel et al., 2007a). After nerve injury, 
30-50% of rats developed mechanical allodynia that lasted 14-days post-injury, with 
mechanical hyperalgesia and cold allodynia also evident in some rats. Interestingly, 
there was no correlation between sensory changes and needle size used to initiate 
injury, and there was no difference in sensory changes between tibial or sural minor 
nerve injuries.  
 Perhaps a more clinically relevant model that those listed above, Guo et al 
(2004) induced a number of CRPS-I signs and symptoms after initiating a rat tibial 
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fracture and casting for four weeks (Guo et al., 2004). Around 31% of CRPS cases 
may indeed by the result of distal tibial fractures (Sarangi et al., 1993). After fracture 
and casting, animals developed mechanical allodynia that lasted 16 weeks, as well 
as edema and hyperthermia. Increased cytokines in the hind paw skin and 
decreased mineral bone density was also observed. After glucocorticoid treatment, 
edema and hyperthermia were attenuated; however, mechanical allodynia wasn’t 
affected. After application of a neurokinin-1 (NK-1) antagonist and soluble TNF-
alpha receptor, mechanical allodynia was reversed, suggesting that Substance P 
and TNF-alpha may play important roles in CRPS-I symptomatology.  
 The above-mentioned rat models each possess some features similar to 
CRPS symptoms. As mentioned by Wilson and colleagues (2005), there is a need 
for validation of existing standards and the generation of new models that can 
recapitulate CRPS’s unique features (Wilson et al., 2005). Each animal model briefly 
explained above lacks in representing most symptoms of CRPS. Thus, a chronic 
post-ischemia pain (CPIP) model developed by Coderre et al (2004) through 
ischemia-reperfusion injury may represent the literature’s best option for the study of 
CRPS-I (Coderre et al., 2004). 
 
1.6.1 CPIP Model 
 
Coderre et al (2004) was able to produce a neuropathic pain-like syndrome in 
rats after initiating a reperfusion injury due to prolonged hindpaw ischemia. In this 
model, anesthetised rats were subjected to complete ischemia of one hindpaw, 
through use of a tight fitting ring, for 3 hours. Hyperalgesia to noxious mechanical 
stimuli and cold, as well as mechanical allodynia were evident and lasted for at least 
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four weeks post injury in most animals. Spontaneous pain behaviours, such as 
licking, shaking and favouring of the hindpaw were also observed. Spread of 
hyperalgesia and allodynia to the contralateral limb were also observed, similar to 
the spread of symptoms in CRPS-I patients. In addition to sensory changes, rats 
exhibited hyperemia and edema for several hours post-injury, all without ischemia-
induced damage to the tibial nerve (Coderre et al., 2004). 
 CPIP presents a good tool for CRPS study as it displays several symptoms 
that are observed in CRPS patients (Janig & Baron, 2002; van der Laan et al., 
1998). Considering CRPS is most common after fracture, sprain, crush injury and 
surgery (i.e physical injury), this model is clinically relevant as it induces symptoms 
through physical injury: ischemia-reperfusion. This model has been used several 
times in the literature in order to assess the effect of different analgesic/anti-allodynic 
treatments (Laferriere et al,. 2014; Nahm et al., 2014; Kwak et al., 2011; de Mos et 
al., 2009). 
 Coderre and colleagues propose that many cases of CRPS-I are the result of 
microcirculatory abnormalities following IR and persistent inflammation from injury. 
Ischemia-reperfusion injury and inflammation can lead to a persistent state of 
reduced perfusion and/or reduced oxygenation of tissue, which is likely involved in 
the sensitization and activation of afferent innervation of the affected tissue (Coderre 
et al., 2004). This activation and sensitization of muscle nociceptors would result in 
deep, persistent pain, and can lead to the central sensitization that contributes to 
mechanical allodynia and hyperalgesia. This means that chronic sensory 
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disturbances present in CRPS-I patients may be strongly linked to the inflammatory 
changes and microvascular deficits occurring after ischemia-reperfusion injury. 
 While CPIP provides evidence for the development of inflammatory and pain 
symptoms after ischemia-reperfusion injury similar to CRPS-I, it would benefit from 
functional analyses before and after injury, considering CRPS-I results in significant 
functional deficits and behavioural changes in patients. Additionally, it may also 
provide a proper means for the testing of other potential therapeutics. 
 
1.7 HEME OXYGENASE 
It may surprise many, but carbon monoxide (CO) – the so-called “silent killer” 
gas – is endogenously produced in the body via the heme oxygenase (HO) system 
during heme metabolism (Bauer et al., 2008). As displayed in Figure 1.2, heme from 
hemoglobin is converted to biliverdin by HO enzyme, resulting in the formation of CO 
and ferrous iron (Fe2+) byproducts (Kikuchi et al., 2005). Biliverdin is then quickly 
converted to bilirubin through the biliverdin reducatase. 
 Heme oxygenase is present is three isoforms: HO-1, HO-2 and HO-3. HO-1, 
which is in high abundance in the liver, spleen, vascular endothelial cells and 
smooth muscle, is inducible in response to oxidative stress, hypoxia, heavy metals 
and cytokines (Ryter & Otterbein, 2004; Ryter et al., 2002). HO-2 is constitutively 
found and expressed under homeostatic conditions; it is found primarily in neuronal 
cells, liver, heart, vascular endothelial cells and smooth muscle tissue (Maines, 
1997). The function of HO-3 is not well understood. 
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The HO system has often been associated with cytoprotective functions. The 
anti-oxidant properties are evident in all byproducts of this system (Motterlini & 
Foresti, 2014; Ryter et al., 2002). Both biliverdin and bilirubin have been found to be 
potent scavengers of peroxyl radicals, as well as inhibiting the effect of other 
mutagens (T. W. Wu et al., 1991). Ferrous iron, a byproduct of heme breakdown, 
has also been found to reduce the formation of iron free radicals, contributing to the 
cytoprotective effect of HO.  Last, but definitely not least, CO is often regarded as 
the most important player in the action of HO (Maines, 1997; Motterlini et al., 1998; 
Otterbein et al., 1999). CO has been shown to be effective in diminishing the 
severity of microvascular dysfunction after ischemia, as well as effective in reducing 
inflammation and cell injury.  
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Figure 1.2. Heme catabolism: conversion of heme to bilirubin through heme 
oxygenase and biliverdin reductase, with carbon monoxide and iron as 
byproducts. 
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1.7.1 Carbon Monoxide 
  At normal conditions, CO exists as a colourless, tasteless and odourless gas 
that is often the product of incomplete combustion (Varon et al., 1999). Currently, the 
leading cause of death by poisoning in the United States is due to CO intoxication 
(Meredith & Vale, 1988; Varon et al., 1999). Upon CO exposure, many detrimental 
side effects may begin to appear, including headache, nausea, vomiting, impaired 
memory, confusion and dizziness. Death is said to occur when carboxyhemoglobin 
levels reach 50-80% (Burg, Ryter and Otterbein 2004).  
Although there seems to be a number of reasons why carbon monoxide 
should never be considered for use as a therapy, investigations into its uses in many 
unique settings are currently underway and are showing promise for its potential as 
a treatment in several conditions. 
In 2001, Fujita and colleagues showed the paradoxical rescue of ischemic 
lung tissue by CO in a HO-1 deficient murine model (Fujita et al., 2001). They found 
that inhaled CO was able to potentiate fibrinolysis by suppressing the induction of 
the gene encoding plasminogen activator inhibitor-1 in phagocytes. They concluded 
that suppression of this hypoxia-induced protein was the result of action through 
soluble guanylate cyclase (Fujita et al., 2001). From this work, and several other 
from the late 1990’s and early 2000’s, the proposition of using CO in a clinical setting 
in the future has been garnering attention. 
  In 2008, a review by Foresti and colleagues outlined the promises and 
challenges associated with the use of CO in therapy. In examining inhaled CO, they 
found that there were indeed several studies showing remarkable results in the 
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treatment of inflammatory processes and cardiovascular disorders, in pre-clinical 
models; however, they could not ignore the inherent toxic effects CO can produce if 
uncontrolled amounts were delivered (Foresti et al., 2008). They concluded that 
administration of gaseous compounds in a clinical setting would come with many 
difficulties and potential complications; they suggested the use of carbon monoxide-
releasing molecules (CO-RMs) would provide a much more clinically applicable 
therapeutic option. 
1.7.1.1 Inhaled CO 
 
Exogenous application of CO through inhalation has been investigated in 
several studies and has been shown to have beneficial effects (Fujita et al., 2001; 
Mishra et al., 2006; Ott et al., 2005); however, CO toxicity is still a very serious and 
potential risk. CO binds haemoglobin at approximately 220 times the strength 
oxygen does (Motterlini, 2007). This significant difference in affinity poses potential 
risks of reducing the oxygen-carrying capacity, resulting in hypoxia, or the formation 
of carboxyhemoglobin (HbCO) molecules, resulting in CO-poisoning. Although the 
level of CO delivered through inhalation could be minimized so as to reduce the 
levels of HbCO, CO poisoning is poorly understood and cannot rely solely on HbCO 
levels as indication of toxicity (Foresti et al., 2008). HbCO levels, however, are still 
good markers to predict the amount of CO present in the body; literature states that 
a proportion of 15-20% HbCO is not detrimental and is the biological threshold for 
CO tolerance (Foresti et al., 2008). Beyond, or around, this biological threshold and 
co-mediated injury is likely to occur in most. 
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In examining the effect of inhaled CO on lung disease or injury, several 
studies have showed positive effect. Otterbein and colleagues (1999) found inhaled 
CO provided protection against hyperoxic lung injury; they were the first to suggest 
anti-inflammatory and anti-apoptotic actions of CO (Otterbein et al., 1999). Beneficial 
effects of inhaled CO were confirmed in models of allergen-induced asthma 
(Chapman et al., 2001), lung transplantation (Song et al., 2003), oxidative lung injury 
(Otterbein et al., 2003), and lung hypertension (Zuckerbraun et al., 2006). 
Interestingly, Clayton and colleagues (2001) challenged this positive view of CO 
effects in their study that showed no benefits after CO treatment (Clayton et al., 
2001).  
Inhaled CO has provided benefit in systemic inflammation and the 
cardiovascular system as well. In several in vitro and in vivo models, CO was able to 
reduce the production of inflammatory cytokines TNF-alpha and interleukins.  In a 
lung transplantation model, inhaled CO was able to prevent ischemia-reperfusion 
injury (Kohmoto et al., 2006). It was also found that administration of CO provided 
full protection even in the absence of HO-1 (Otterbein, 2002). 
Although inhaled CO provides remarkable benefits in several pre-clinical 
models, its administration in a clinical setting may be very limited. 
 
1.7.1.2 Carbon Monoxide-Releasing Molecules (CO-RMs) 
As a result of the potential risks associated with inhaled CO therapy, a novel 
class of transition metal carbonyl compounds have been developed, in order to 
deliver exogenous CO through an oral or injectable route (Foresti et al., 2008; 
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Motterlini et al., 2002; Motterlini, Mann, et al., 2005). Carbon monoxide-releasing 
molecules (CO-RMs), have the general chemical formula M(CO)xLy, whereby “M” is 
the transition metal, “x” the number of CO ligands and “y” the number of additional 
ligands (Santos-Silva et al., 2011). 
The first CO-RMs developed, CORM-1 and CORM-2, were lipid soluble, fast-
releasing compounds (Figure 1.3).  CORM-1 and CORM-2 both have half-lives 
equal to or less than one minute (Motterlini, Mann, et al., 2005). As a result of the 
need for solubility in solutions like DMSO or ethanol, these CO-RMs proved difficult 
to administer, as they are relatively inapplicable to biological solutions. Eventually, a 
water-soluble ruthenium-based CO-RM, CORM-3, was developed. 
CORM-3 (molecular formula Ru(CO)3Cl(glycinate), also a short half-life 
compound, is stable at physiological conditions (pH 7.4, 37oC, aqueous solution). 
With a half-life of approximately one minute, CORM-3 rapidly liberates CO through a 
ligand substitution reaction (Motterlini, Mann, et al., 2005). Both CORM-3 and a 
newer CO-RM called CORM-A1, are promising compounds for the use of CO-RMs 
in therapy (Motterlini, Sawle, et al., 2005). 
Newer CO-RMs have been developed as of late, such as CORM-368, 
CORM-401, CORM-371, CORM-409, and CORM-313; however, limited 
investigations have been completed in terms of their therapeutic properties. These 
newly synthesized CO-RMs are manganese-containing compounds (rather than 
ruthenium) and therefore may provide less risk as a potential drug. 
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Figure 1.3. Chemical structures of three carbon monoxide-releasing 
molecules (CO-RMs). Adapted from (Gullotta et al., 2012). 
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1.7.1.3 CORM-3 
 One of the key limitations of the first CO-RM molecules developed was its 
solubility. Lipid soluble molecules tend to be more difficult to administer clinically and 
are therefore less favourable. In order to confer solubility in aqueous solutions, 
biochemists were able to add a glycine amino acid molecule to the metallic carbonyl 
compound (Motterlini, Mann, et al., 2005). With this amino acid addition, the half-life 
of the compound remained similar to CORM-1 and -2 at about 1 minute, assuming in 
physiological solutions. Motterlini and colleagues were able to show positive results 
for CORM-3’s ability to release CO molecules upon administration in a rat model and 
provide beneficial vasodilation. By also showing that CORM-3 administration was 
safe up to a concentration of 500 µM, Motterlini was able to meet all of the criteria 
required for a potential clinical carrier for pharmaceutical carbon monoxide 
(Motterlini, Mann, et al., 2005).  
 CORM-3 has been used in both in vivo and in vitro modelling of several 
disorders: downregulation of inflammation, cardio-protective effects, anti-thrombotic 
effects, effects on hypertension, bactericidal effects, effects on intraocular pressure, 
nephrotoxicity, and pain. Evidence for beneficial effects of CORM-3 has been 
described by many authors (Bani-Hani et al., 2006; Desmard et al., 2009; Failli et al., 
2012; Hervera et al., 2012; Lawendy et al., 2014; Mizuguchi et al., 2009; Sato et al., 
2001; Sawle et al., 2005; Stagni et al., 2009; Tayem et al., 2006; Urquhart et al., 
2007; Varadi et al., 2007). 
 The mechanism(s) by which CORM-3 acts are still relatively unknown. Some 
scholars state that CORM-3 (and CO-RMs in general), may act differently than their 
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inhalational counterpart (Gullotta et al., 2012); however, based on the evidence that 
CO possesses beneficial functions in controlling vessel tone, apoptosis, cell 
proliferation, platelet aggregation, inflammation, neurotransmission and ion channel 
activation, most researchers agree that CO (including CORM-3-generated CO) act 
through several different signalling pathways (Alberto & Motterlini, 2007; Motterlini et 
al., 2003). Specifically, the effect of CO appears to be mediated by cyclic GMP 
(cGMP), which is part of a soluble guanylate cyclase signalling cascade (Failli et al., 
2012; Foresti et al., 2004; Fujita et al., 2001). Another pathway by which CORM-3 
has been stated to act is the mitogen-activated protein kinase (MAPK) (Chlopicki et 
al., 2006; Mishra et al., 2006; Zhang et al., 2003). While both the soluble guanylate 
cyclase and MAPK pathways are suggested to mediate CO action, other possible 
targets may include calcium-activated potassium channels, cytochrome P450 or the 
mitochondrial respiratory chain (Chlopicki et al., 2006). 
 
1.7.2  CO and Pain 
 Studies investigating CO and CO-RMs have been strongly suggesting their 
beneficial effects in multiple disorders; however, a question arises whether CO could 
have an effect on pain and/or sensory disorders. In 2012, Hervera and colleagues 
discovered that CORM-3-derived CO was able to reduce mechanical allodynia, as 
well as thermal hyperalgesia and allodynia in sciatic injury in mice. They suggested 
that CORM-3 might produce these effects through inhibition of nitric oxide (NO) 
pathways and synthesis, as well as through inhibition of microglial activation, 
	  	  
48 
implicated in the initiation and maintenance of neuropathic pain (Hervera et al., 
2012; Watkins et al., 2001).  
 Several other studies have investigated the effects of CO in pain (Bijjem et 
al., 2013; Hervera, Gou, et al., 2013; Hervera, Leanez, et al., 2013; Negrete et al., 
2014); however, none have examined the effect of CO on functional behaviour. 
 
1.8 FUNCTIONAL TESTING AND CRPS 
The clinical presentation of CRPS is dominated by a combination of sensory 
and autonomic symptoms. However, mounting evidence indicates that many 
patients with CRPS suffer from some forms of motor dysfunction and movement 
disorders (Birklein et al., 2000; Schwartzman & Kerrigan, 1990; Veldman et al., 
1993). With the growing consensus being that movement disorders should be 
included in the diagnostic criteria of CRPS, functional analysis is an area in need of 
exploration. 
Functional analysis can be performed through several methods. In rodent 
models, however, there are two chief methods used to assess functional changes: 
(1) electrophysiological testing and (2) locomotor analysis. In electrophysiological 
testing, by using electrodes and isolated muscle, contraction amplitude and 
frequencies can be measured and analyzed in comparison with the afferent 
stimulation provided. These, however, do not reveal the true function of the limb. 
Locomotion, as a consequence of neurological stimulation, muscle 
contraction and coordination between limbs, is a better measure of function in all 
models. Several methods of locomotor analysis exist.  
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Open field locomotion, was initially developed to examine behaviour of 
rodents (Hall, 1934). It utilizes an open field apparatus to acquire locomotor 
information through the capture of images, or through the use of infrared photocells. 
Recently, open field locomotion analysis has begun to examine the use of infrared 
illumination for capturing data, rather than visible light, which could interfere with an 
animal’s behaviour (Aragao Rda et al., 2011). Although useful for examining some 
behavioural and locomotor changes in the rat, these open field locomotion methods 
are time-consuming and cannot measure some very important parameters of gait. 
Other methods of locomotor analysis include the paper paw print method, the 
electric grid method, as well as Cheng’s glass plate method (Afelt et al., 1983; Basso 
et al., 1995; H. Cheng et al., 1997; de Medinaceli et al., 1982). Each of these, 
however, has its own set of drawbacks and cannot provide a rapid and objective 
means to examining a large set of gait parameters.  
1.8.1 CatWalk™ Automated Gait Analysis 
 The CatWalk™ automated gait analysis system is a computerized functional 
assessment tool for rats and mice, rapidly and objectively quantifying many 
parameters of gait. The system has been validated in numerous animal models, 
including spinal cord injuries (Koopmans et al., 2005; Miyagi et al., 2013), allodynia 
(Gabriel et al., 2007; Vrinten & Hamers, 2003), sciatic nerve injury (Bozkurt et al., 
2008; Chiang et al., 2014) and arthritis (Angeby-Moller et al., 2008; Ferland et al., 
2011). 
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 This system uses a 1-metre long glass-floored walkway with a green light 
source attached, such that the light is completely internally reflected in the glass. 
Once a paw makes contact with the glass, light escapes and scatters; this can be 
detected by a digital video camera fixed below. After videos are recorded, and each 
paw print has been classified, the CatWalk™ software calculates static and dynamic 
parameters of gait (Appendix A). 
 To ensure precision in acquiring data, rodents must be thoroughly trained 
before the commencement of baseline tests. Ideally, rodents should be able to run 
from one end of the walkway to the other in an un-interrupted fashion. Some factors, 
however, may significantly alter gait parameters. Gabriel et al (2007) demonstrated 
that a 40% body mass increase affects many gait parameters. It is therefore crucial 
to the experiment to ensure rodents stay within a bracket of body mass. 
 In comparison with von Frey mechanical stimulation testing – the gold 
standard test for measuring allodynia – Vrinten and Hamers (2003) demonstrated 
that the CatWalk™ provided similar results, suggesting gait analysis may be a more 
rapid, reproducible and objective tool for measuring allodynia.  
 
1.8.2 Functional Testing in CRPS Patients 
In examining and publicizing CRPS, pain is usually the main focus, and not 
the disabilities that come with it. The pain is often so debilitating that joints become 
locked, bones become osteoporotic and muscles become spastic and atrophy. 
Disuse of the affected limb is a common feature of CRPS and is often the result of 
patients trying to avoid potential painful stimuli. This can lead to skin changes (colour 
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and temperature) as well as hyperalgesia (Butler, 2001). By avoiding the use of the 
limb, patients may operant condition themselves, reinforced by the avoidance of 
actual pain and even the reduced anxiety of anticipated pain. This would result in the 
prevention of de-sensitization as well as the elimination of any tactile or 
proprioceptive input that may help restore central signal processing of the limb (M. 
Stanton-Hicks et al., 1998; H. K. Watson & Carlson, 1987). Disuse may also result in 
a lack of natural blood pumping from limb musculature, perhaps resulting in an 
accumulation of catecholamines or tachykinin that could further exacerbate CRPS 
symptoms (Drummond et al., 2001; Weber et al., 2001).  
  As a result, Wilfrid Janig proposed several research directions towards 
understanding the functional deficits associated with CRPS (Wilson et al., 2005). He 
suggested the generation of new models that recapitulate the syndrome’s unique 
features. The CPIP model mentioned earlier does indeed present several features 
observed in CRPS patients; however, no study has been found to examine the 
deficits accumulated through functional testing modalities like gait analysis. 
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1.9 AIM OF THIS THESIS 
Despite the breadth of work dedicated to understanding CRPS-I, there are 
still several gaps in knowledge, and no cemented conclusion as to specific cause(s). 
With recent studies observing microvascular deficits in CRPS-I patients (Bellingham 
et al., 2014), the development of the CPIP model by Coderre et al has provided a 
suitable avenue for the investigation of both pathophysiology and treatment options. 
However, as suggested by Wilson et al (Wilson et al., 2005), future directions in the 
study of this syndrome must be geared towards validation of existing models of 
CRPS and generation of new models that recapitulate the unique features of this 
syndrome; changes in gait and motor abnormalities are certainly unique features 
that need to be assessed. 
As a modulator of several signalling pathways that affect vascular properties, 
CORM-3 may be a good potential treatment for vascular deficit disorders. With the 
understanding that microvascular dysfunction may play an important role in the 
development and maintenance of CRPS-I, the investigation into the use of CORM-3 
as treatment of CRPS-I is warranted.  
Therefore, the aim of this thesis was twofold: to examine the use of the 
CatWalk™ automated gait analysis system in quantifying functional changes 
following initiation of CRPS-like symptoms in the CPIP rodent model, and to 
examine the potential therapeutic use of CORM-3 in CPIP. 
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CHAPTER 2:  FUNCTIONAL ASSESSMENT OF ALLODYNIA IN A RAT 
MODEL OF COMPLEX REGIONAL PAIN SYNDROME TYPE-
1 USING AUTOMATED GAIT ANALYSIS 
 
2.1 INTRODUCTION 
Complex regional pain syndrome type-1 (CRPS-I) is a debilitating chronic 
pain condition, characterized by hyperalgesia and allodynia. Many studies suggest a 
major factor in the development and maintenance of CRPS-I may be inflammation 
and/or microcirculatory dysfunction (Albrecht et al., 2006; Bellingham et al., 2014; 
Coderre & Bennett, 2010), while others suggest it to be a disease of the central 
nervous system (Janig & Baron, 2002). Most clinicians however, prefer to believe 
the syndrome to be multifactorial and is not driven by a single mechanism of injury 
(Janig & Baron, 2006). Both of types I and II of CRPS develop after trauma and 
present similar symptoms; however, CRPS-I occurs without nerve injury and the 
severity of its symptoms are disproportionate to the severity of the trauma (Janig & 
Baron, 2006). 
A rodent model of CRPS-I, called chronic post-ischemia pain (CPIP), 
developed by Coderre et al, induces microcirculatory dysfunction through ischemia-
reperfusion injury (Coderre et al., 2004). Consequent allodynia (mechanical and 
cold), edema, hyperemia and hyperalgesia were observed to mimic those in patients 
suffering from CRPS (Coderre et al., 2004; Harden et al., 2013; Janig & Baron, 
2002; van der Laan et al., 1998; van der Laan et al., 1999). However, no objective 
assessment of function was included in this model. 
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Automated gait analysis has been proposed to be a quality indicator of 
behaviour and mechanical allodynia in many rodent pain and/or injury models 
(CatWalk™).  This computer-assisted technique allows for rapid quantification of 
both static paw and dynamic inter-limb gait parameters (Angeby-Moller et al., 2008; 
Bozkurt et al., 2008; Ferland et al., 2011; Gabriel et al., 2007; Gabriel et al., 2009; 
Hamers et al., 2001; Huehnchen et al., 2013; Koopmans et al., 2005; Miyagi et al., 
2013; Sakuma et al., 2013; Vogelaar et al., 2004; Vrinten & Hamers, 2003). 
Depending upon the model used, automated gait analysis has varying results as a 
measure of allodynia.  In some chronic pain models (Gabriel et al., 2009), the 
CatWalk™ system detected allodynia at different time points compared to standard 
assessments of mechanical allodynia (the von Frey test, (Chaplan et al., 1994)), and 
may also have understated measures of allodynia (Gabriel et al., 2009). 
Alternatively, a study using carrageenan injections to induce neuropathic pain 
provided significant correlation between CatWalk™ parameters and von Frey data 
(Gabriel et al., 2007). Analysis of gait changes using the CatWalk™ system as a 
measure of mechanical allodynia may be dependent on the model of chronic pain 
being used (Gabriel et al., 2009). At this time, to our knowledge, there have been no 
reports that examine the usefulness of the gait analysis to assess allodynia in the 
CPIP model of CRPS-I. In addition, in keeping with the more stringent diagnostic 
criteria for research purposes, functional tests should be required in many models. 
Therefore, the purpose of this study was to investigate whether an automated 
gait analysis system, the Catwalk™, would provide a more thorough and complete 
assessment of allodynia in the CPIP model of CRPS-I.  
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2.2 METHODS 
2.2.1 Animal Description and Care 
The experimental protocol was approved by the Canadian Council on Animal 
Care at the University of Western Ontario. Animals were cared for in accordance to 
the guidelines of the Committee for Research and Ethical Issues of the International 
Association for the Study of Pain (IASP). All animals were housed in pairs with 
access to food and water ad libitum. 
Male Wistar rats (185 – 260 g) were anesthetized with inhalational isoflurane 
(5% induction, 2% maintenance) in 1:1 oxygen/nitrogen gas mixture. Body 
temperature was measured using a rectal probe thermometer and maintained at 37 
degrees Celsius using a heating lamp. CPIP was generated by ischemia-reperfusion 
(IR) injury of the right hind limb, as per Coderre et al (Coderre et al., 2004). Briefly, 
ischemia was induced by application of tourniquet (#4 silk, Johnson and Johnson) 
around the distal portion of the right hind limb, completely occluding the blood flow 
(i.e. no-flow ischemia), and maintained for 3 hours. Reperfusion was initiated by a 
tourniquet release. Tourniquet placement was at a standardized distance distal to 
the tibial tuberosity of the distal portion of the hind limb, differing slightly from 
tourniquet placement by Coderre and colleagues. 
In a separate group of animals, the tourniquet was applied just proximal to the 
knee joint (proximal IR group), so as to induce ischemia over the entire lower aspect 
of the limb. The position of each tourniquet was standardized to minimize variation in 
injury. 
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2.2.2 Experimental Groups 
Rats were randomized into three groups: CPIP (n=9), proximal IR (n=5) and 
sham (n=8). Compared with the CPIP group, the proximal IR group differed in the 
location of where the ischemia-reperfusion injury was induced. Sham animals 
underwent all procedures as the CPIP and proximal IR groups, but the tourniquet 
was not tightened. 
 
2.2.3 Mechanical Allodynia Testing 
To assess mechanical allodynia, hindpaw withdrawal thresholds to von Frey 
filament stimulation were measured. Animals were placed on a raised, mesh-floored 
platform and covered with a transparent plastic box. Animals were left for a minimum 
of 5-10 minutes to allow for familiarization to the new environment before 
measurements were taken. The plantar surfaces of both right and left hind paws 
were stimulated by von Frey filaments with calibrated bending forces (grams) 
(Stoelting Co., Wood Dale, IL) in order to determine a 50% withdrawal response 
threshold, similar to the method developed by Chaplan et al (Chaplan et al., 1994). 
Filaments were applied 10 times each, in ascending strength (1.0 g to 15.0 g). 
Withdrawal thresholds were determined by a positive response observed a minimum 
of 5 times at a specific filament strength. Positive responses were recorded as a lift 
or lick. Withdrawal thresholds were measured pre-injury, as well as 5, 7, 8, 9, 10 and 
14 days post-injury. 
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2.2.4 Functional Analysis of Gait 
The CatWalkTM (Noldus Information System, Wageningen) is an automated 
gait analysis system that delivers a large collection of gait parameters, including paw 
print area, duty cycle, weight load, swing phase and step regularity index. Static gait 
parameters, including paw prints and weight load, as well as dynamic parameters 
like duty cycle, are automatically measured and calculated by the system software. 
Definitions of each parameter are listed in Table 2.1.  
The system consists of a glass plate platform illuminated with fluorescent 
tube; when contact is made with the glass, light is reflected downwards toward a 
high-definition camera, connected to a computer, where it is then interpreted by the 
accompanying software. 
In order to assess gait, animals were trained to walk the length of the glass 
plate platform end-to-end, prior to the induction of ischemia. A minimum of five days 
of training was conducted for each animal until each animal was competent at 
walking the length of the platform without interruption. General, dynamic and paw-
specific gait parameters were collected pre-injury, as well as 1, 5, 7, 8, 9, 10 and 14 
days post-injury. At least 3 runs, that were uninterrupted and 1-3 seconds in 
duration, were recorded for each trial.  
 
2.2.5 Statistical Analysis 
Using GraphPad Prism® software, repeated measures two-way analysis of 
variance (ANOVA) was performed to assess differences in gait parameters, as well 
as paw withdrawal thresholds, compared to baseline and control values.  
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Table 2.1.  CatWalk™ automated gait analysis tool parameters and 
definitions. Static and dynamic gait parameters were collected and 
assessed using the assisting software package. The parameters 
discussed in the results section were those showing the largest 
changes from baseline measurements. 
 
Static Gait 
Parameter Definition 
Dynamic Gait 
Parameter Definition 
Paw Print Area 
(mm2) 
Total area of glass plate 
in contact with paw during 
stance phase 
Duty Cycle 
 (%) 
Stance as a percentage 
of step cycle 
(=stance/step cycle) 
Paw Print Width 
(mm) 
Total width of paw print  
Step Cycle  
(s) 
Duration in seconds 
between two 
consecutive initial 
contacts of the same 
paw (stance + swing 
phases) 
Paw Print Length 
(mm) 
Total length of paw print 
Stance Phase 
Duration  
(s) 
Duration in seconds of 
contact of paw with 
glass plate 
Weight Load 
(a.u/pixel) 
Paw pressure is indicated 
by light intensity. Weight 
load is mean intensity 
(arbitrary units, a.u) per 
pixel 
Swing Phase 
Duration  
(s) 
Duration in seconds of 
no contact of paw with 
glass plate 
  
Step Regularity 
Index  
(%) 
Number of normal step 
sequence patterns 
(NSSP) relative to the 
total number of paw 
placements (PP) 
(=(NSSPx4)/PP x 100% 
  
Swing Speed  
(distance units/s) 
Speed of the paw 
during swing phase 
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Bonferroni post-tests were also performed. To determine if CatWalk™ parameters 
correlated with the gold standard paw withdrawal thresholds, Pearson correlation 
coefficients were calculated. A p<0.05 was considered significant. 
 
2.3 RESULTS 
2.3.1 CPIP And Proximal IR 
For almost the entire duration of ischemia, the right hind paw (ipsilateral) was 
observed as cold and cyanotic in all animals. Directly after the removal of the 
tourniquet, evidence of severe edema and hyperemia were observed. Rats 
displayed spontaneous pain behaviours, such as shaking, licking and lifting of the 
injured limb. In the CPIP group, by 14 days post-reperfusion injury, most animals 
displayed a slightly atrophied and less robust right hind limb when compared to the 
contralateral limb. Animals in the proximal IR group showed less substantial 
changes in spontaneous pain behaviours over the duration of the experiment. Sham 
animals displayed no spontaneous pain behaviours or changes in the appearance of 
the right hind limb. 
 
2.3.2 Mechanical Allodynia 
Ischemia-reperfusion injury led to the development of mechanical allodynia in 
both the CPIP and proximal IR groups, as demonstrated by decreased paw 
withdrawal thresholds of the ipsilateral limbs (Figure 2.1). In the CPIP group, by 7 
days post-reperfusion injury, paw withdrawal thresholds of the injured right hind limb 
decreased to 2.444 ± 0.689 g, from 13.889 ± 0.735 g at baseline (p<0.001).  
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Figure 2.1.  Paw withdrawal thresholds (PWT) of the ipsilateral/right hindpaw. 
PWTs were assessed using mechanical stimulation via von Frey 
filaments and analyzed via two-way repeated measures ANOVA. 
PWTs of the ipsilateral/right hindpaw showed significant differences in 
both CPIP and proximal IR groups; however, only the CPIP group 
displayed sustained differences over the entire time course. (* p<0.05 
from proximal IR group, † p<0.05 from baseline) Error bars shown 
represent the standard error of the mean (SEM). 
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The right hind limb displayed reduced paw withdrawal thresholds throughout the 
duration of examination. At 14 days post-reperfusion injury, paw withdrawal 
thresholds were still significantly lower than baseline values (5.556 ± 0.801 g, 
compared to 13.889 ± 0.735 g at baseline (p<0.05)). At 7 days post-reperfusion 
injury the contralateral limb also displayed a mild, though not significant, reduction in 
the paw withdrawal thresholds (12.444 ± 1.334 g in CPIP versus 13.889 ± 0.735 g at 
baseline, n.s.) (Figure 2.2). 
In the proximal IR group, ipsilateral paw withdrawal thresholds decreased 
from 15.00 ± 0.00 g at baseline to 6.00 ± 1.265 g after ischemia-reperfusion injury 
(p<0.05). Paw withdrawal thresholds of the contralateral limb did not significantly 
change from baseline, similar to the CPIP group. Withdrawal thresholds of the 
injured (ipsilateral) hind limb were restored, without intervention, to baseline levels 
by 14 days post-injury (Figure 2.2). 
Sham animals displayed no significant changes in paw withdrawal thresholds 
for the duration of the experiment (data not shown). 
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Figure 2.2.  Paw withdrawal thresholds (PWT) of the contralateral/left 
hindpaw. PWTs were assessed using mechanical stimulation via von 
Frey filaments and analyzed via two-way repeated measures ANOVA. 
No significant differences in paw withdrawal thresholds were observed 
in the contralateral/left hindpaw. Error bars shown represent the 
standard error of the mean (SEM). 
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2.3.3 Functional Analysis of Gait 
Automated gait analysis detected several alterations of gait parameters post-
reperfusion. Both static (paw print area, paw print width, paw print length and weight 
load) and dynamic (duty cycle, stance phase and swing cycle) parameters markedly 
changed by 24 hours post-reperfusion injury (Figures 2.3 to 2.7). Paw print area 
decreased from the baseline of 56.18 ± 8.38 mm2 in CPIP and 76.27 ± 18.65 mm2 in 
proximal IR group to 1.113 ± 0.77 mm2 and 4.834 ± 2.97 mm2, respectively, after 1 
day reperfusion injury (p<0.05) (Figure 2.3).  By 5 days post-injury, print area in the 
proximal IR group was restored back to baseline values. At 14 days post-injury, print 
area of the CPIP group was still significantly decreased, at 25.39 ± 5.305 mm2 
(p<0.05).  
Print length and width demonstrated very similar significant trends (Figures 
2.4 and 2.5). Using the Pearson correlation coefficient, all paw print parameters in 
the CPIP group displayed correlation with paw withdrawal threshold data (p<0.05). 
Correlation data is shown in Table 2.2. 
Duty cycle in the CPIP group decreased after injury from the baseline of 53.2 
± 2.1% to 6.8 ± 4.5% at 1 day post-injury (p<0.05) (Figure 2.6). The change in duty 
cycle was sustained throughout the course of the experiment (32.6 ± 4.2% at 14 
days post-injury, p<0.05). Correlation with paw withdrawal thresholds, using the 
Pearson correlation coefficient, was confirmed in the CPIP group (p<0.05).  
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Figure 2.3.  Paw print area of the right hindpaw (mm2) in CPIP, proximal IR 
and sham groups. Print area was calculated using the CatWalk 
system software and analyzed via two-way repeated measures 
ANOVA. CPIP animals show significant difference from sham group 
after ischemia-reperfusion injury for the duration of the experiment. 
Print area of proximal IR animals restore to baseline quickly after 
injury. († p<0.05 from proximal IR group, * p<0.05 from baseline) Error 
bars shown represent the standard error of the mean (SEM). 
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Figure 2.4.  Paw print length of the right hindpaw (mm). After ischemia-
reperfusion injury, CPIP animals demonstrated substantially lower print 
length than sham and proximal IR groups through the duration of 
testing. († p<0.05 from proximal IR group, * p<0.05 from baseline) Print 
area was calculated using the CatWalk system software and analyzed 
via two-way repeated measures ANOVA. Error bars shown represent 
the standard error of the mean (SEM). 
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Figure 2.5.  Paw print width of the right hindpaw (mm). Print width was 
markedly lower in CPIP animals after ischemia-reperfusion injury 
compared to proximal IR and sham animals. († p<0.05 from proximal 
IR group, * p<0.05 from baseline) Print width was calculated using the 
CatWalk system software and analyzed via two-way repeated 
measures ANOVA. Error bars shown represent the standard error of 
the mean (SEM). 
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Figure 2.6.  Changes in Duty Cycle (stance phase/swing phase + stance 
phase). Duty cycle was calculated using the CatWalk system software 
and analyzed via two-way repeated measures ANOVA. After injury, 
duty cycle in CPIP animals was significantly different from both 
proximal IR and sham animals, for the duration of the experiment. († 
p<0.05 from proximal IR group, * p<0.05 from baseline) Error bars 
shown represent the standard error of the mean (SEM). 
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Figure 2.7.  Swing speed of the right hindpaw. Swing speed was calculated 
using the CatWalk system software and analyzed via two-way 
repeated measures ANOVA. CPIP animals demonstrated a smaller 
swing speed than proximal IR and sham groups throughout 
experiment; however, swing speed at 14 days post-injury was not 
different from baseline speed in CPIP animals. († p<0.05 from proximal 
IR group, * p<0.05 from baseline) Error bars shown represent the 
standard error of the mean (SEM). 
 
 
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
0
500
1000
1500
2000
2500
CPIP
proximal IR
Sham
*
†
* * * * * * *
† † † †
Days post-injury
Sw
in
g 
Sp
ee
d 
(m
m
/s
)
†
	  	  
89 
Table 2.2. Correlation coefficients comparing gait parameters and 
mechanical stimulation. Using the Pearson Correlation statistical test 
in our GraphPad Prism software, we compared gait parameters with 
the gold standard mechanical stimulation measurements for mechanic 
allodynia. 
 
 
 
Gait Parameters p-value Correlation Coeffecient 
Duty Cycle 0.0019 0.8760 
Paw Print Area 0.0001 0.9609 
Paw Print Length 0.0015 0.8817 
Paw Print Width 0.0011 0.9002 
Step Regularity Index 0.2320 0.2700 
Swing Speed 0.0654 0.5253 
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Step regularity index decreased from 89.8 ± 4.3% at baseline to 11.7 ± 7.8% 
(p<0.05) at 1 day after injury, however it was restored to baseline without 
intervention by 9 days post-injury. At 14 days post-injury, regularity index returned to 
89.3 ± 4.5%. No correlation was observed using the Pearson correlation coefficient. 
Swing speed decreased from the pre-injury value of 1071.0 ± 82.7 mm/s to 
215.1 ± 180.3 mm/s at 1 day after injury, (p<0.05), and increased back to 928.6 
mm/s ± 77.39 by 14 days post-injury in the CPIP group. In the proximal IR group, the 
swing speed decreased from the pre-injury value of 1242.6 ± 101.3 mm/s to 242.5 ± 
159.6 mm/s at 1 day after injury and returned to 1556.2 ± 73.8 mm/s at 14 days 
post-injury. Although significantly different from proximal IR and sham groups at 14 
days post-injury, swing speed in CPIP animals was not markedly different from its 
baseline value. Swing speed showed no correlation with von Frey data, as well. 
(Figure 2.7) 
Sham animals showed no significant changes in gait parameters throughout 
the entire length of the experiment. 
 
2.4 DISCUSSION 
In the present study, we demonstrated the use of automated gait analysis 
(CatWalk™) to rapidly and objectively quantify allodynia in the CPIP model of 
CRPS-I. Four gait parameters proved to display results correlating with the gold 
standard von Frey mechanical stimulation tests, which were paw length, width, and 
area as well as duty cycle. Through successful validation with gait analysis, we have 
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provided a more objective, practical and perhaps more clinically relevant model of 
CRPS-I.  
Sensitivity was substantially heightened and spontaneous pain behaviours 
were observed after injury, resulting in symptoms similar to those presented in 
patients with CRPS-I (Coderre et al., 2004). After comparing the distal tourniquet 
placement to one placed proximal to the knee joint, paw withdrawal thresholds 
confirmed that tourniquet placement in the CPIP animals produced chronic 
mechanical allodynia symptoms, whereas proximal tourniquet placement resulted in 
paw withdrawal thresholds returning to baseline levels by 14 days post-injury. 
Although sensitivity did indeed increase with IR injury in the proximal IR group, these 
symptoms were not long lasting. This suggests the CPIP model is more 
representative of chronic pain symptoms of CRPS-I compared to the proximal IR 
group. The proximal IR group was added in order to both examine chronic pain 
symptoms using a different tourniquet placement, as well as to assess muscular 
tissue injury in the rodent after ischemia-reperfusion injury; however, our results 
indicate the proximal IR group does not display a chronic pain response.  
Mechanical stimulation using von Frey filaments demonstrated a persistent 
increase in sensitivity and symptoms of allodynia in the CPIP group. Correlating with 
results from the development of the CPIP model (Coderre et al., 2004), paw 
withdrawal threshold was significantly lower than that of the pre-injury. Although the 
O-ring band used to initiate ischemia in the original model was not used, our use of a 
ligature (#4 silk, Johnson & Johnson) showed similar results, suggesting that the 
same tension was applied.  
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Confirmation of the CPIP model through mechanical stimulation testing 
(Coderre et al., 2004) allowed for comparison with and examination of gait analysis, 
through the automated CatWalkTM method. After sensitivity and gait analysis, some 
correlation in mechanical allodynia measurements was observed. The decrease and 
sustainment of paw withdrawal thresholds observed after ischemia-reperfusion injury 
confirm the CPIP model produces mechanical allodynia; changes in gait parameters, 
correlating well with changes in paw withdrawal thresholds, also suggest that 
animals experienced allodynia. Meanwhile, the proximal IR animals did not display 
persistent or correlating gait parameter changes, which again suggests that the 
CPIP model best displays CRPS-I symptoms. This is important as it demonstrates 
that the automated gait system is indeed assessing changes as a result of allodynia 
rather than muscle injury, which would likely be greater in those animals undergoing 
IR injury with a proximally placed tourniquet. In the proximal IR group though, 
standard error is greater in both mechanical stimulation and gait analyses, perhaps 
suggesting more variable occlusion of blood flow and less standardization of injury.  
Gait parameters showed significant changes through the 14-day testing 
period. At one day post-injury, all gait parameters were significantly different than 
those at baseline (i.e. pre-injury); however, only duty cycle and paw print parameters 
(area, length and width) maintained the significant changes throughout the duration 
of the experiment. The time of contact of one paw in one single stepcycle, defined as 
the stance phase duration, can be directly related to pain perception in the rat; 
therefore, duty cycle, which is the ratio of stance phase duration to stepcycle, has 
been suggested to be the gait parameter most indicative of mechanical allodynia 
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(Gabriel et al., 2009). Static paw print parameters such as area, width, and length, 
also provide indication of potential pain symptoms, as it would be reasonable to 
expect a reduction in paw use when said paw is experiencing pain symptoms. 
Weight load did not show chronic changes in contrast to other gait parameters. This 
suggests that even with similar loads placed on the limb, the limb use is functionally 
different in the CPIP animals. 
Slight differences in gait parameter values between the control and sham 
group were observed, especially in static paw print parameters. Sham animals were 
slightly lesser in mass (and as such, smaller in size) upon commencement of testing 
which may explain these findings. No significant differences were observed in 
dynamic gait parameters. This was expected, even with the slight differences in 
mass between the groups, as it has been shown that a 40% variation in mass is 
required for significant difference in paw print intensity to be observed (Gabriel et al., 
2009). 
Although gait parameter changes and von Frey tests differed in their 
assessment of mechanical allodynia, these may be explained through the 
mechanisms underlying the responses observed. Reaction to von Frey filament 
stimulation involves minimal central processing (Gabriel et al., 2009), whereas gait is 
a centrally controlled daily activity that can be affected by several factors, including 
pain (Jordan et al., 2008; MacKay-Lyons, 2002; Pearson, 2000). Since human 
chronic pain conditions are also centrally processed, gait is relevant to human 
experiences and therefore its analysis may be more clinically applicable. Pain and 
allodynia are obvious factors that impact gait, but behaviours changes and 
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neurological and/or muscular tissue damage definitely have a role as well. In 
relevant literature, reversible nerve damage is usually not evident until at least 3-4 
hours of ischemia, and in the CPIP model publication by Coderre and colleagues, no 
nerve injury was observed through light microscopy (Coderre et al., 2004) Although 
muscle tissue damage may impact our gait measurements, our correlation data 
suggests that the gait changes were significantly correlated with changes in 
mechanical allodynia, according to our gold standard mechanical stimulation tests. 
These markedly correlated changes are shown in Figure 2.2.   
Validation of the CPIP model provides additional support for the notion of 
microcirculatory dysfunction and inflammation may be part of the pathophysiology 
driving CRPS-I signs and symptoms. A recent clinical study by Bellingham et al 
observed a decrease in deep tissue oxygen saturation in CRPS-I patients using near 
infrared spectroscopy, supporting the theory that deep tissue hypoxia is part of the 
pathogenesis behind CRPS-I, providing more validity to an 
inflammation/microvasculature dysfunction-based CRPS-I model (Bellingham et al., 
2014). 
As stated by Gabriel et al, the use of the CatWalk™ method for assessment 
of mechanical allodynia needs to be carefully restricted to specific injury models 
(Gabriel et al., 2009). This study, through comparison of von Frey test and 
CatWalkTM analysis, suggests that functional examination of gait provides a powerful 
additional tool for the study of mechanical allodynia in the CPIP model of CRPS-I. 
Supplementation with the CatWalk™ system provides an additional significant 
measure of function and can provide a more robust account of the pain experience 
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in the rodent. Ultimately, comparing therapeutic interventions in the management of 
CRPS-I is currently very difficult; the addition of objective, practical and functional 
testing adds substantially to our ability to develop more effective therapies. 
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CHAPTER 3:  Carbon Monoxide Reduces the Level of Allodynia in a 
Rodent Model of Complex Regional Pain Syndrome Type-1 
 
3.1 INTRODUCTION 
Complex regional pain syndrome type-1 (CRPS-I) is a clinical condition where 
disproportional symptoms of pain and mechanical allodynia are experienced after 
distal extremity trauma (Bellingham et al., 2014; Harden, 2010; Sandroni et al., 
1998; P. Wilson et al., 2005; P. R. Wilson, 2010). Sprains, crush injuries, surgery 
and fractures have all been known to lead to a CRPS-I diagnosis (Bean et al., 2014; 
Harden, 2010; Sandroni et al., 1998). 
Recently, studies by Coderre and colleagues have led to the development of 
a rodent model of CRPS-I, through initiation of the “slow-flow/no-reflow” 
phenomenon by ischemia-reperfusion (IR) injury, triggering chronic post-ischemia 
pain and allodynia, similar to those observed in patients suffering from CRPS-I. 
Studies suggest that the pain perceived by some CRPS-I patients may indeed be 
the result of I-R injury and the subsequent inflammation developed as a result of 
microcirculatory changes from the IR injury (Bellingham et al., 2014; Coderre & 
Bennett, 2010; Coderre et al., 2004).  Another recent study has demonstrated 
impaired tissue oxygen saturation in the hands of patients with CRPS-I, 
demonstrating that deep tissue hypoxia and microvascular dysfunction are involved 
in the pathogenesis (or at least maintenance) of CRPS-I (Bellingham et al., 2014). 
Lately, attention has been directed to the potential use of carbon monoxide 
(CO) in a clinical setting, despite the detrimental and deadly effects commonly 
associated with it. As a byproduct of the heme oxygenase (HO) system, CO is 
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endogenously produced at low doses and, along with HO-1, has been correlated to 
either the degree of injury/disease or increased survival in a variety of syndromes 
(Foresti et al., 2008).  
 Although the mechanisms of CO action are poorly understood, exogenous 
application through inhalation has been shown to elicit protection against multiple 
organ injury (MOI), inflammation, apoptosis, cell proliferation, vasoconstriction and 
hypertension (Chapman et al., 2001; Foresti et al., 2008; Fujita et al., 2001; Mishra 
et al., 2006; Otterbein et al., 1999; Song et al., 2003). However, CO application 
through inhalation is a clinically challenging therapy as carboxyhemoglobin (HbCO) 
levels increase quickly, possibly leading to hypoxia and further co-mediated injury 
(Clayton et al., 2001). Recent developments have led to the production of CO-
releasing molecule-3 (CORM-3), which is a water soluble, quick-releasing transition 
metal carbonyl capable of efficiently releasing CO in the bloodstream (Foresti et al., 
2008; Foresti et al., 2004; Yabluchanskiy et al., 2012). Compared with CO 
inhalation, CORM-3 application does not significantly alter HbCO levels (Foresti et 
al., 2008; Foresti et al., 2004; Yabluchanskiy et al., 2012).  
The anti-inflammatory and vasodilatory actions of CO are perhaps the most 
intriguing and potentially useful. Previous studies have shown that the inflammatory 
reaction after IR injury is reduced after application of CORM-3 (Lawendy et al., 
2014).  Inflammation and oxidative stress resulting from ischemic conditions appear 
to be the underlying factors for several chronic pathologies. Recent work suggests 
that microvascular dysfunction and inflammation may be factors contributing to the 
development of one such pathology, CRPS-I (Bruehl, 2010). 
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Previously, in order to investigate symptoms of CRPS-I, mechanical allodynia 
has been assessed using mechanical stimulation via the von Frey method. This, 
however, does not test the function of the affected limb. The ‘CatWalkTM’ automated 
gait analysis system rapidly and objectively quantifies several parameters of gait and 
has been shown to be a quality supplement to the von Frey method in some injury 
models (Angeby-Moller et al., 2008; Bozkurt et al., 2008; Chiang et al., 2014; 
Ferland et al., 2011; Gabriel et al., 2007; Sakuma et al., 2013; Vrinten & Hamers, 
2003).  
Through the use of a previously validated model of CRPS-I, the purpose of 
this study was to examine the effects of CORM-3 on the symptoms of CRPS-I, 
specifically on symptoms of allodynia. 
 
3.2 METHODS 
3.2.1 Animal Description and Care 
The experimental protocol was approved by the Canadian Council on Animal 
Care at the University of Western Ontario. Animals were cared for in accordance to 
the guidelines of the Committee for Research and Ethical Issues of the International 
Association for the Study of Pain (IASP). All animals were housed in pairs with 
access to food and water ad libitum. 
Male Wistar rats (185-260g) were anesthetized with inhalational isoflurane 
(5% induction, 2% maintenance) in a 1:1 oxygen/nitrogen gas mixture.  
Chronic post-ischemia pain (CPIP) was generated by ischemia-reperfusion 
(IR) injury of the right hindpaw, as per Coderre et al (Coderre et al., 2004). A 
tourniquet (#4 silk, Johnson and Johnson) was applied to the distal portion of the 
	  	  
102 
right hind limb in each animal, completely occluding the blood flow. Tourniquet 
application was maintained for 3 hours. The position of each tourniquet was 
standardized so as to minimize variation in injury, as stated above in Chapter 2. 
Reperfusion was then initiated by release of the tourniquet.  
 
3.2.2 CORM-3 
 CORM-3 has been synthesized by us, in accordance with previously 
published methods (Lawendy et al., 2014; Motterlini & Otterbein, 2010). CORM-3, or 
its inactive counterpart, iCORM-3, were administered to animals at a dose of 
10mg/kg, given IP. 
 
3.2.3 Experimental Groups 
Twenty male Wistar rats were randomized into two groups: control group, 
treated with iCORM-3 (n=9), and an experimental group, treated with CORM-3 
(n=11). Both CORM-3 and iCORM-3 groups were administered their respective 
injections at 7 days post-injury via intra-peritoneal injection. 
 
3.2.4 Mechanical Allodynia Testing 
To assess allodynia, hind paw withdrawal thresholds (PWT) to von Frey 
filament stimulation were measured. Animals were placed on a raised, mesh-floored 
platform and covered with a transparent plastic box. To allow for familiarization to 
the new surroundings, animals were left for a minimum of 10 minutes before 
measurements were taken. The plantar surfaces of both right and left hind paws 
were stimulated with von Frey filaments (Stoelting Co., Wood Dale, IL) in order to 
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determine a 50% withdrawal response threshold in accordance with similar 
techniques found in literature (Bennett, 2010). Filaments were applied 10 times each 
in ascending strength (1.0 g to 15.0 g). Withdrawal thresholds were determined by a 
positive response, observed a minimum of 5 times, at a specific filament strength. 
Positive responses were recorded as a lift or lick. Withdrawal thresholds were 
measured pre-injury, as well as 5, 7 (pre- and post-injection), 8, 9, 10, and 14 days 
post-reperfusion. 
 
3.2.5 Functional Analysis of Gait 
The CatWalkTM (Noldus Information System, Wageningen) is an automated 
gait analysis system that delivers a large collection of gait parameters, including paw 
print area, duty cycle, weight load, swing phase and step regularity index. Static gait 
parameters, including paw prints and weight load, as well as dynamic parameters 
like duty cycle, are automatically measured and calculated by the system software.  
The system consists of a glass platform illuminated by a fluorescent tube; 
when contact is made with the glass, light is reflected downwards toward a high-
definition camera, connected to a computer, where it is then interpreted by the 
accompanying software. 
In order to assess gait, animals were trained to walk the length of the glass 
plate platform end-to-end, prior to the induction of ischemia. A minimum of five days 
of training was conducted until each animal was competent at walking the length of 
the platform without interruption. During training, animals were motivated to traverse 
the walkway by the use of sweet treats. General, dynamic and paw-specific gait 
parameters were collected pre-injury, as well as 1, 5, 7 (pre- and post-injection), 8, 
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9, 10 and 14 days post-injury. Each trial had a minimum of 3 runs, and only runs 1-3 
seconds in duration were accepted. 
 
3.2.6  Intravital Video Microscopy (IVVM) 
In some iCORM-3 (n=5) and CORM-3 (n=5) animals, microscopic evaluation 
of skeletal muscle microcirculation was undertaken using intravital video microscopy 
(IVVM). 
The extensor digitorum longus (EDL) muscle was isolated and prepared, as 
described previously (Lawendy et al., 2011; Potter et al., 1993). Briefly, the tibialis 
anterior and lateral gastrocnemius muscles were divided through blunt dissection to 
expose the EDL. A suture ligature was applied around the distal tendon of the EDL 
and the tendon was then cut from its bony attachment in order to reflect the muscle 
onto the microscope stage, with its arterial and venous blood flow intact. Once 
prepared, animals were carefully placed on the stage of an inverted microscope 
(Nikon Diaphot 300) and the EDL reflected onto a slide with saline bath containing 
5µg/ml each of the fluorescent vital dyes bisbenzimide (BB; Ex. 343nm, Em. 483nm) 
and ethidium bromide (EB; Ex. 482nm, Em. 616nm). As BB stains the nuclei of all 
cells while EB stains the nuclei of only those cells with damaged cell membrane, 
EB/BB ratio provided an index of tissue injury. A cover slip was then placed atop the 
EDL. The temperature of the exposed muscle and the animal itself was maintained 
at 37 degrees Celsius by the use of a heat lamp. Care was taken to minimize time 
between EDL exposure and the first microscope recording. 
The inverted microscope was connected to a charge-coupled device camera 
(Dage-MTI VE1000), a time-date generator (WJ-810, Panasonic), as well as a 
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computer. To provide appropriate white light illumination, flexible fibre-optic guides 
were positioned above the EDL.  
Microvascular perfusion and leukocytes within the post-capillary venules were 
recorded by translumination with 20x and 40x objectives, respectively, in five 
randomly chosen fields of view. Fluorescence microscopy was used to visualize the 
BB and EB from the same fields of view that had been selected for the measurement 
of capillary perfusion. At the conclusion of the experiment, rats were euthanized by 
an overdose of isoflurane anesthetic agent. 
 
3.2.7 Offline Video Analysis 
3.2.7.1 Perfusion Analysis  
Capillary perfusion was measured in each 60-second clip at 20x objective 
(final magnification of 700x), as per previously validated methodology (Lawendy et 
al., 2014). Perfusion was quantified by counting the number of continuously-
perfused (CPC), non-perfused (NPC) and intermittently perfused (IPC) capillaries 
crossing 3 equidistant parallel lines drawn on the computer monitor, perpendicular to 
the capillary axis.  Capillaries with continuous flow were deemed CPC, those with 
flow interrupted at any point during the 60-second clip were deemed IPC, and those 
with no flow throughout the 60-second clip were deemed NPC. These values were 
expressed as the percent of total capillaries per field of view. 
 
3.2.7.2 Analysis of Leukocytes 
Leukocyte activation, i.e. rolling and adherence, was measured in post-
capillary venules at 40x objective (final magnification of 1400x). Thirty second clips 
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from each 45 second recording were randomly chosen; the total number of rolling 
and adherent leukocytes were measured during this time and expressed per 1000 
µm2. Venular area was measured using ImageJ (NIH, Bethesda, MD). Adherent 
leukocytes were defined as those cells remaining stationary over the entire duration 
of the 30-second clip. 
 
3.2.7.3 Injury Analysis 
BB and EB are nuclear dyes; BB labels nuclei of all cells, as it is membrane-
permeable, while EB is membrane impermeable and therefore only stains cells with 
injured (permeable) membranes. EB labeling cannot distinguish between cell injury 
and cell death, as a wide range of injury may cause increased membrane 
permeability. Tissue injury in the randomly chosen fields of view was assessed by 
counting the number of EB- and BB-labelled nuclei, and expressed as EB/BB ratio. 
 
3.2.8 Statistical Analysis 
Repeated measures two-way analysis of variance (ANOVA), using GraphPad 
Prism® software, was performed to assess differences in gait parameters, paw 
withdrawal thresholds, tissue perfusion, muscle injury, leukocyte rolling and 
leukocyte adherence between iCORM-3 and CORM-3-treated animals.  Statistical 
difference was defined at p<0.05; Bonferroni post-tests were also performed. 
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3.3 RESULTS 
3.3.1 CRPS-I Model 
For the duration of ischemia, the right hind paw (ipsilateral) was observed as 
cold and cyanotic in all animals. Directly after the removal of the tourniquet, 
evidence of severe edema and hyperemia were observed. Upon recovery, rats 
displayed spontaneous pain behaviours, such as shaking, licking, and lifting of the 
injured limb. By 14 days post-reperfusion injury, most animals displayed an 
atrophied and less robust right hind limb when compared to the contralateral limb. 
Two animals did not develop CRPS-I like symptoms or display pain behaviours, and 
hence were excluded from further analysis. 
 
3.3.2 Mechanical Allodynia 
Ischemia-reperfusion injury led to increased tactile sensitivity, as 
demonstrated by decreased paw withdrawal thresholds of both the ipsilateral and 
contralateral limbs. By 7 days post-reperfusion injury, paw withdrawal thresholds of 
the injured right hind limb decreased from 14.25±0.41g at baseline to 3.00±0.59g 
(p<0.001) (Figure 3.1). At 7 days post-reperfusion injury, the left hind limb displayed 
paw withdrawal thresholds at an average of 11.25±0.85g, compared to 14.25±0.41g 
at baseline (p<0.05). (Figure 3.1) 
In the right hind limb, paw withdrawal thresholds were significantly less than 
baseline levels in the iCORM-3 group throughout the duration of the experiment. 
However, in the experimental group, upon administration of CORM-3 at 7 days post-
reperfusion injury, accelerated restoration of paw withdrawal thresholds was 
observed.  
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Figure 3.1.  The effect of ischemia-Reperfusion on paw withdrawal threshold 
(PWT) of the ipsilateral/right and contralateral/left hindpaws. 
PWTs were assessed using mechanical stimulation via von Frey 
filaments. PWTs of both the ipsilateral/right and contralateral/left 
hindpaw showed significant differences after reperfusion injury. (* 
p<0.05 from iCORM-3, † p<0.05 from baseline). Error bars shown 
represent the standard error of the mean (SEM). 
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Compared to application of iCORM-3, application of CORM-3 significantly 
increased paw withdrawal thresholds (6.636±0.96g versus 2.222g±0.49g, p<0.05) at 
1 hour post-injection. By 7 days post-injection (14 days post-reperfusion injury), right 
hind limb paw withdrawal thresholds of CORM-3-administered animals were 
restored to baseline levels. (Figure 3.2). 
In the left hind limb, restoration of paw withdrawal thresholds back to baseline 
values was observed quickly without intervention. CORM-3 had no effect on the 
contralateral limb. 
 
3.3.3 Functional Analysis of Gait 
Gait analysis using the CatWalkTM method detected several alterations of gait 
parameters post-reperfusion injury. Both static and dynamic parameters of gait 
dramatically changed by 24 hours post-reperfusion injury, including paw print 
parameters, weight load, duty cycle, stance phase and swing cycle, among several 
others. However, by 7 days post-injury, most gait parameters were restored to 
baseline without intervention, with the exception of paw print parameters (area, 
length and width) and duty cycle. Application of CORM-3 did not affect duty cycle, 
resulting in no significant difference from baseline. Similarly, paw print length and 
width showed no differences between CORM-3 and iCORM-3 injections. Paw print 
area demonstrated a trend of an increased rate of restoration of print area after 
application of CORM-3; however, no significance was achieved (Figure 3.3). 
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Figure 3.2. The effect of CORM-3 on paw withdrawal threshold (PWT). CORM-
3 was administered at 7 days post-injury and PWTs were assessed via 
mechanical stimulation testing at 1 hour post-injection, and at 1, 2, 3 
and 7 days post-injection. PWTs of the ipsilateral/right hindpaw 
displayed significant changes after CORM-3 injection. No changes in 
PWTs were observed in the contralateral hindpaw of iCORM-3 and 
CORM-3 animals. (* p<0.05 from iCORM-3, † p<0.05 from baseline). 
Error bars shown represent the standard error of the mean (SEM). 
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Figure 3.3.  Paw print area of the right hindpaw (mm2). Paw print was calculated 
using the automated gait analysis software tool. († p<0.05 from 
baseline) Error bars shown represent the standard error of the mean 
(SEM). 
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3.3.4 Microcirculation 
3.3.4.1 Muscle Perfusion 
 When compared to CORM-3 animals at 14 days, CPC of the EDL in CORM-3 
animals were significantly increased when compared to iCORM-3 animals (87±1% 
versus 77±3%, p<0.05) (Figure 3.4). No significant difference between IPC in the 
CORM-3 and iCORM-3 animals was observed (3±1% versus 6±2%, n.s.). 
 There was no significant difference in NPC in CORM-3 animals compared to 
iCORM-3 animals at 14 days post-reperfusion injury (10±1% versus 17±3%, n.s.), 
although a trend for increased perfusion with CORM-3 was observed.  
 
3.3.4.2 Activated Leukocytes 
Decreased adherence of leukocytes was observed in CORM-3 animals when 
compared to iCORM-3 animals (0.7836±0.116 leukocytes/1000µm2 in CORM-3 
group versus 2.482±0.556 leukocytes/1000µm2 in iCORM-3 group, p<0.05). No 
significant difference in rolling leukocytes within the EDL was observed (8.320 ± 
1.807 leukocytes/30s/1000µm2 in CORM-3 group versus 9.12 ± 2.992 
leukocytes/30s/1000µm2 in iCORM-3 group, n.s.) (Figure 3.5). 
 
3.3.4.3 Injury 
The level of cell injury was not significantly different between iCORM-3 and 
CORM-3 animals after intervention. Animals administered with CORM-3 
demonstrated a 0.3202±0.1229% level of injury, compared with 0.4588±0.1369% 
(n.s.) in iCORM-3-treated animals (Figure 3.6). 
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Figure 3.4.  Skeletal muscle capillary perfusion. Values are expressed as a 
percentage of the total number of capillaries per field of view within 
EDL muscle. Significant difference in CPC was observed between 
CORM-3 and iCORM-3 animals. (* p<0.05 from iCORM-3). No 
statistical differences were observed in IPC or NPC between CORM-3 
and iCORM-3 groups. Error bars shown represent the standard error of 
the mean (SEM). 
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Figure 3.5.  Leukocyte activation (adherence and rolling) in post-capillary 
venules of the extensor digitorum longus after IVVM. Significant 
difference in the number of adherent leukocytes was observed 
between iCORM-3 and CORM-3 animals. (* p<0.05 from iCORM-3). 
Error bars shown represent the standard error of the mean (SEM). 
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Figure 3.6.  The effect of CORM-3 on cellular injury within the skeletal muscle. 
The index of injury was assessed as the ratio of EB-labeled nuclei to 
BB-labeled nuclei (EB/BB). No statistical difference was observed, 
although there was a trend towards a decrease in CORM-3-treated 
animals. Error bars shown represent the standard error of the mean 
(SEM). 
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3.4 DISCUSSION 
The chronic post-ischemia pain model, established by Coderre et al (Coderre 
et al., 2004) and validated with gait analysis, appeared to successfully model 
symptoms of CRPS-I in the rat, allowing for a comprehensive examination of 
possible therapeutic interventions. In the present study, we demonstrated the effect 
of CORM-3 on the reduction of mechanical allodynia symptoms, as well as its anti-
inflammatory and vasodilatory action through direct observation of microcirculation.  
Prolonged ischemia-reperfusion injury led to production of mechanical 
allodynia in the injured, as well as the uninjured, rat hind limbs. Consistent with 
previous results (Coderre et al., 2004), animals displayed reduced paw withdrawal 
thresholds after injury. Although this CRPS-like symptom was observed in both hind 
limbs, allodynia was much more pronounced in the ischemia-injured limb. In animals 
treated with inactive CORM-3, the reduced paw withdrawal threshold was 
maintained throughout the duration of the experiment; CORM-3 injection restored 
paw withdrawal thresholds to baseline levels, demonstrating a reduction in the pain 
sensation and tactile sensitivity. Previously, other CO-RMs, (i.e. CORM-2), have 
shown to have similar anti-nociceptive effects, as demonstrated in nerve constriction 
models and inflammation-based models (Hervera, Gou, et al., 2013; Negrete et al., 
2014). Unlike CORM-2, CORM-3 is water-soluble, making it more clinically relevant 
therapeutic, if found to be effective. 
 While the mechanisms of CORM-3 actions are not fully understood, studies 
suggest that some may involve the suppression of oxidizing compound production 
and up-regulation of free radical scavengers (Mizuguchi et al., 2010; Patterson et al., 
2014). This is consistent with the idea that CRPS-I may be induced or maintained 
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through free radical generation and inflammatory processes, as treatment with other 
free radical scavengers also appeared to reduce mechanical allodynia symptoms 
(Coderre et al., 2004). Thus, our data may also provide support for inflammatory and 
microvascular dysfunction as important factors in the development and maintenance 
of CRPS-I. 
 As suggested previously (Gabriel et al., 2007; Gabriel et al., 2009), the 
functional limb assessment by the use of the CatWalkTM automated gait analysis 
system may be limited to certain injury models. In the case of the CPIP as a model 
of CRPS-I, we have previously identified certain gait parameters as being important 
in the correlation between von Frey filament testing for allodynia and gait analysis. 
These included several paw print parameters (length, width, area) and duty cycle. In 
response to ischemia-reperfusion injury, some gait parameters changed 
significantly. Application of CORM-3 had no effect; however, there was a trend for 
increased paw print measurements (Figure 3.3). Given that changes in gait are a 
more complex measure of allodynia as compared to mechanical stimulation, it is 
reasonable to assume that pain sensation might not have as dramatic an effect. 
Previously, changes in CatWalkTM gait parameters have been observed after certain 
treatments, however, these were delivered multiple times over the course of the 
injury period (Koopmans et al., 2009), as opposed to a single injection of CORM-3 in 
our study. Thus, potential changes in gait parameters in response to CPIP should be 
explored in the future, with multiple dosing regimen. 
 It has been suggested that CRPS-I may be maintained by microcirculatory 
abnormalities (Bellingham et al., 2014; Coderre et al., 2004; Millecamps & Coderre, 
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2008). Consistent with this, our IVVM data in the CPIP model shows that the muscle 
tissue in the allodynic limb appears to have clear microvascular deficiencies. In 
response to CPIP, cell injury, leukocyte activation and capillary perfusion all show 
significant changes from the control parameters of sham animals previously 
published in ischemia studies (Potter et al., 1993). At 7 days post-injury, CORM-3 
altered leukocyte adhesion within the post-capillary venules of the EDL (Figure 3.5). 
Additionally, CORM-3 also appeared to alter the degree of capillary perfusion 
(Figure 3.4). These results confirm the anti-inflammatory and vasodilatory actions of 
CO (McCarter et al., 2004; Mizuguchi et al., 2009), perhaps providing reason for the 
reduced pain sensation and the trend for restored gait. While not significant, there 
was a trend towards a reduced tissue injury in CORM-3-treated animals (Figure 3.6). 
Perfusion, which may be affected by leukocyte activity (Granger & Senchenkova, 
2010), is an important factor in functional use of a tissue. Thus, increased tissue 
perfusion may help to rationalize the observed trend towards restoration of gait 
parameters. Delivery of CORM-3 at seven days post-reperfusion injury may give it 
little opportunity to act to reduce cell injury, since circulating endothelial progenitor 
cells may have repaired damaged endothelium within seven days.  
 Considering the effects of CORM-3-released CO on the observed changes of 
IVVM parameters in CPIP, restoration of microvascular perfusion may underlie the 
mechanism by which CORM-3-derived CO is able to alleviate allodynia symptoms. 
Thus, given the notion of microvascular dysfunction as one of the important factors 
in the development and maintenance of CRPS-I, improving capillary perfusion and 
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reducing leukocyte activation could explain the significant difference in the 
withdrawal thresholds of CORM-3-administered animals. 
Previously, magnetic resonance spectroscopy has demonstrated that CRPS 
patients have hypoxic muscles in the affected limbs, which causes difficulty in 
regulating normal limb functions (Heerschap et al., 1993). Transcription factor NFκB, 
which has been shown to be involved in ischemia, inflammation and sensitization 
pathologies, appears to be potently inhibited by CO preconditioning (Sun et al., 
2008). Some studies have shown a direct link of NFκB to the development of 
allodynia in the CPIP model; thus it has been suggested that NFκB may play a role 
in the pathogenesis of CRPS-I (de Mos et al., 2009). Application of NFκB inhibitor 
was able to relieve both mechanical and cold allodynia symptoms. Therefore, it 
could be hypothesized that application of CORM-3 may interfere with this potential 
pathogenic mechanism of CRPS-I. 
Another molecule recently linked to CRPS-I pathogenesis is the inflammatory 
cytokine TNF-alpha (Maihofner et al., 2005; Munnikes et al., 2005; Sabsovich et al., 
2008; Wesseldijk et al., 2008a, 2008b). Increasing evidence suggests that TNF-
alpha plays a critical role in the pathogenesis of altered pain sensation. Although it 
has been previously shown that TNF-alpha returns to baseline levels quickly after a 
reperfusion injury (Bihari et al., 2014), Kramer et al found elevated TNF-alpha levels 
in the skin of affected limbs of CRPS-I compared to “normal” fracture and 
osteoarthritis patients (Kramer et al., 2011). This local, but not systemic, increase in 
TNF-alpha may be linked to the well-documented peripheral effects of TNF-alpha on 
nociceptor sensitization (Julius & Basbaum, 2001).  Considering the ability of 
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CORM-3 to block the release of TNF-alpha levels during reperfusion (Lawendy et 
al., 2014), perhaps the substance acts to reduce allodynia sensation in CPIP model 
through a reduction in TNF-alpha levels. Further molecular examination of harvested 
tissue from these animals is required to explore this. 
Inflammation of the vasa nervorum around peripheral nerves (neuritis) may 
be involved in CPIP (Coderre & Bennett, 2008); this suggests that relief of the 
inflammation may reduce pain symptoms associated with CRPS-I. Several other 
studies have demonstrated CO-RMs to be effective in reducing allodynia in a chronic 
sciatic nerve constriction model of neuropathic pain (Hervera, Gou, et al., 2013; 
Hervera, Leanez, et al., 2013). Given the range of pain models where CO was able 
to provide relief of symptoms (including both nerve constriction and inflammatory 
pain), CORM-3-derived CO may play an active role in several pathways of pain 
sensation, either directly or indirectly. However, further comprehensive study into 
both CORM-3 mechanisms and pain sensation would be required. 
Treatment options currently available for CRPS-I patients are relatively 
extensive. One of the common treatments is a regional nerve block to the affected 
limb; however, recent studies have shown that regional anesthesia does not 
consistently block pain, especially in ischemic limbs (Kucera & Boezaart, 2014). 
Considering the fact that many patients do not respond to the available treatment, 
the development of additional therapeutic options for CRPS-I is needed. A holistic 
interpretation of the results from mechanical stimulation testing, gait analysis and 
IVVM suggests that CORM-3 reduces allodynia symptoms in the CPIP rodent model 
of CRPS-I. Considering that pain is the most important factor in patients’ quality of 
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life, the reduction in sensitivity, even without significant changes in gait, after 
administration of CORM-3 is still an important finding. Considering the anti-
inflammatory and vasodilatory actions of CO, the reduction in allodynia symptoms 
after CORM-3 administration again suggests that CRPS-I may have some 
microvascular abnormalities associated with the maintenance of its symptoms. Thus, 
our data suggests that CO, along with its current potential application in several 
other pathologies, may have clinical relevance as a therapeutic agent in CRPS-I. 
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CHAPTER 4:  GENERAL DISCUSSION AND CONCLUSIONS 
 
 
4.1 OVERVIEW OF RESULTS 
 
 
4.1.1 CPIP Model 
 
 This thesis focuses on the assessment and potential treatment of CRPS-I, 
using the chronic post-ischemia pain (CPIP) model. The model has proved to be a 
reliable representation of many CRPS-I-like symptoms, acquired through an insult 
known to often result in CRPS. In keeping with the proposed hypotheses for the 
pathophysiology of CRPS-I, the CPIP model appears to present what is perhaps the 
best animal model for examination of CRPS-I mechanisms and assessment of 
potential treatments. Compared with others, CPIP provides the hallmark symptoms 
of CRPS-I, including chronic hyperalgesia, allodynia (both cold and mechanical), 
inflammatory signs and spontaneous pain behaviours. The results of this thesis also 
show that the CPIP model produces behavioural and functional deficits similar to 
those observed in CRPS-I.  
 
4.1.2 Gait Analysis 
 
 Chapter 2 describes the use of an automated gait analysis system (the 
CatWalkTM)  to assess functional changes in the CPIP model.  
The data showed that gait analysis using the CatWalkTM system was able to 
detect an injury after ischemia-reperfusion injury. Four gait parameters (duty cycle 
and the three paw print parameters) statistically correlated with the chronic allodynia 
measurements taken via the gold standard of von Frey filament stimulation. While 
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other gait parameters showed significant changes immediately after injury, most 
normalized quickly to baseline by the end of our 14-day testing cycle.  
In a separate group of animals, we showed that the CPIP model was an 
effective model for the development of long-lasting allodynia symptoms. CPIP 
animals maintained lower threshold of von Frey stimulation compared to the 
proximal IR group, which received a similar IR insult, only proximal to where the 
tourniquet had been placed in the CPIP group. The results validated the CPIP model 
in its ability to develop chronic allodynia. Interestingly, the CPIP group showed that 
the injury paradigm was not the major factor in affecting gait alterations; rather the 
gait alterations were probably secondary to allodynia. However, the physiology of 
tourniquet position just below the knee (both in this model and in general) is not well 
defined, and this may affect a range of kinematic parameters.  
Chapter 2 provides us with an objective method for assessing functional 
changes in the CPIP model of CRPS-I. As stated by the new Budapest diagnostic 
criteria for CRPS (Harden et al., 2007), functional assessment is beneficial in 
examining symptomatology of CRPS. By providing an additional measure for the 
total pain experience in the rat, we may be able to better test the effects of potential 
therapeutics in the treatment of CRPS-I. 
 
 
4.1.3 The Effect of CORM-3 
 
CORM-3 has been found to have some anti-inflammatory, anti-apoptotic and 
vasodilatory properties (Lawendy et al., 2014). Based on this, we aimed to examine 
its use as a potential therapeutic agent in reduction of allodynia symptoms, as well 
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as any gait changes observed in the CPIP model of CRPS-I. In Chapter 3, we 
showed that CORM-3-derived CO carried anti-allodynic effects after an injection at 
seven days post-reperfusion. We demonstrated that CORM-3 was able to increase 
von Frey mechanical stimulation withdrawal threshold values back to baseline within 
seven days post-injection. Consistent with the previous anti-nociceptive vasodilatory 
treatments (Coderre et al., 2004), increased perfusion of EDL capillaries was 
observed after CORM-3 injection. In addition, a decrease in leukocyte adherence 
was found, although no changes in rolling leukocytes or in cell injury were observed 
in CORM-3 treated animals. These results suggest that an inflammatory response, 
albeit a diminished one is still occurring. Considering the length of time, elapsed 
after CORM-3 treatment (i.e. 7 days) that microcirculation was directly visualised, it 
is not unreasonable to see no changes in cell injury between CORM-3 treated and 
CPIP animals, even with the knowledge that CORM-3 has anti-apoptotic properties.  
 Similar to recent work by Hamam et al (Hamam et al., 2014) on compartment 
syndrome (CS), no significant changes in gait parameters were observed after 
CORM-3 application. A trend toward improved function was observed after CORM-3 
injection in both studies; however, dynamic gait parameters were most affected by 
CORM-3 in CS, compared to a trend in static gait parameters in this study. The 
complex nature of gait movements, in terms of central processing, may have 
negated some of the positive effects CORM-3 had on the microvasculature, perhaps 
resulting in a lack of gait improvement. 
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4.2 STUDY LIMITATIONS 
4.2.1  Pain Measurements 
As the CPIP model in rats is a representation of the painful human condition, 
CRPS-I, we are presented with an inherent limitation in regards to pain and its 
measurement. Non-verbal representations of pain and hypersensitivity, using paw 
withdrawal from both noxious and non-noxious stimuli, are measured in the CPIP 
model. One limitation of pain and sensitivity tests is the animal handling required. 
Often, pain tests require that animals be restrained for measurements. In Chapters 2 
and 3, animals were taken from their resting cages and placed in small chambers for 
allodynia testing with von Frey filaments. Studies have found that simple handling of 
rats can cause recruitment of endogenous opioids that can result in delayed 
responses to stimuli, including the stimuli used in our experiments, i.e. von Frey 
filaments (Jorum, 1988; Jorum & Shyu, 1988). In an effort to remove this potential 
limitation, we allowed rats to acclimatize to the new environment for a period of at 
least 10-15 minutes. Even with these additional efforts, some rats tried to escape the 
testing chamber after the 10-15 minute acclimatization period. Escape behaviour 
may suggest that these rats had altered responses to stimuli, perhaps as a result of 
endogenous opiod release. 
 
4.2.2 Animal Model and Age of Rats 
 
In both Chapters 2 and 3, young rats were used to produce CPIP. Animals 
were ordered at a weight of 150-175 g, although a minimum weight of 200 g was 
ensured before inducing the model through I-R injury. What was noticed in both 
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chapters was a resiliency of the rats, as it pertains to their recovery from injury. In 
some rats, no allodynia symptoms developed; these animals were subsequently 
excluded from further testing. Considering that CRPS is more common in adult 
patients, it may be prudent to use older rats in future experiments, in order to 
account for their resilient nature with respect to recovery from any injury and/or the 
development of allodynia symptoms similar to CRPS. 
Other authors have cited a weight gain of 40% as being significant in the 
measurement of several gait parameters (Gabriel et al., 2009). Although no 
significant weight changes were observed in our experiments, the use of older rats 
may help negate any chance of weight gain affecting gait parameters. 
Coderre and colleagues, in the original publication of the CPIP model, used 
pentobarbital injection to anesthetize rats before surgery. In our experiments, we 
used inhalational isoflurane. Although isoflurane has been found to have 
hypotensive and respiratory depression effects, it is an ideal anesthetic to use for 
extended surgical procedures like ours. Also, if temperature is properly maintained 
at normal body temperature, these side effects may be avoided. We ensured rats 
were always approximately 37 degrees Celsius through the use of a heating lamp.  
 
4.2.3 Automated Gait Analysis 
 
To assess functional changes after induction of CPIP to model CRPS-I, we used 
an automated gait analysis system. The CatWalkTM uses the refraction of light from 
an animal’s paw on the glass walkway to capture images. Light is internally reflected 
within the glass and only released once a paw (or any other object) touches the 
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walkway. As a result, error is created if moisture or debris is present on the walkway. 
Rats often urinate small amount at the ends of the walkway and drag that moisture 
towards the centre of the walkway. Efforts were taken to ensure the walkway was 
dry and free from debris at all times, but it was impossible to have all of the recorded 
runs free of any moisture.  
 Several times throughout the experimental time-course rats would drag their 
underside on the glass walkway. The excess contact is normally recorded by the 
system as noise on the CatWalkTM software, creating a difficult situation for the 
software to classify paw prints automatically. As a result, many paw prints had to be 
be manually classified, inherently introducing a source of error.  
Noldus, the CatWalkTM system manufacturer, has just released an improved 
and more advanced analyzing software. Currently, our lab does not have this most 
recent edition, which might prove to be useful in measuring functional changes in our 
model, as well as in several other models of injury. 
 
4.3 FUTURE DIRECTIONS 
 
 Considering the short half-life of CORM-3 in physiological solution, injecting 
CORM-3 multiple times after initiation of the CPIP model may yield different results. 
It may be interesting to see the effects this would have on how quickly paw 
withdrawal thresholds are returned to baseline, or if they would be restored at all. 
 Building on the above direction, and in order to better observe the effects of 
CORM-3, it would be beneficial to perform IVVM on some animals directly after 
injury, as well as at 1, 2, and 3 days post-injection. This approach may provide a 
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better insight into the effect of CORM-3 on the microvasculature, as it may be 
possible to correlate the gradual restoration of paw withdrawal thresholds with the 
changes directly observed within the microvasculature. It may also allow us to 
examine the effects of tourniquet placement and time on microvascular changes of 
the distal portion of the limb. 
 In examining how gait changes are caused by pain-related problems in the 
CPIP model, including a known analgesic pharmacological agent may be useful. 
This approach may help to ascertain the exact link between gait changes and pain 
while monitoring the normalization of gait, similar to the work  of Angeby-Moller and 
colleagues in arthritis studies (Angeby-Moller et al., 2008). 
 Tissues from the skeletal muscle could be harvested from all animals at the 
time of euthanasia; although beyond the scope of this study, these could be used to 
examine the potential mechanisms of action of CORM-3 at a molecular level.  
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4.4 GENERAL CONCLUSIONS 
 
 The work presented in this thesis is the first piece of scientific literature to 
evaluate gait in the CPIP model of CRPS-I. It was hypothesized, based on the 
literature describing other inflammatory conditions, that automated gait analysis may 
be an objective and rapid tool for the assessment of gait changes secondary to 
allodynia. The results presented here suggest that automated gait analysis in the 
CPIP model is indeed a beneficial tool. We found several gait parameters correlating 
with von Frey measurements of allodynia assessment. As CRPS-I patients often 
lose range of motion and general function, as well as develop dystrophy/atrophy of 
the affected limb, using the methodology described in this work we may be able to 
better assess efficacy of potential therapeutics. 
 In the literature, anti-sympathetic and vasodilatory drugs have often appeared 
to reduce mechanical allodynia in CPIP model of CRPS-I. Through the use of the 
known vasodilatory, anti-inflammatory and anti-oxidant properties of CORM-3, this 
work has shown that CO therapy is capable of reducing mechanical allodynia 
symptoms in the CPIP, as indicated by an increase in paw withdrawal thresholds. 
The actual effect of CORM-3 is still unclear; however, with further analysis, 
mechanisms of CORM-3 action may be delineated and assist with improving our 
understanding of the complex pain mechanisms involved in CRPS-I. 
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APPENDIX A – DEFINITIONS OF GAIT ANALYSIS PARAMETERS 
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APPENDIX C – ANIMAL PROTOCOL APPROVAL 
 
 
 	  	  	  	  	  	  	  	  
           11.01.13 
      *This is the original approval for this protocol* 
*A full protocol submission will be required in 2017* 
 
Dear Dr. Lawendy: 
 
Your animal use protocol form entitled: 
 
Direct and Remote Organ Injury Following Hind Limb Compartment Syndrome 
 
Funding agency Orthopaedic Trauma Association – Direct and Remote Organ Injury Following Hind Limb 
Compartment Syndrome – Grant #R4889A04 has been approved by the University Council on Animal Care. 
 
This approval is valid from 11.01.13 to 11.30.17 with yearly renewal required. 
 
The protocol number for this project is 2009-083. 
 
1.  This number must be indicated when ordering animals for this project. 
2.  Animals for other projects may not be ordered under this number. 
3.  If no number appears please contact this office when grant approval is received. 
If the application for funding is not successful and you wish to proceed with the project, request that an 
internal scientific peer review be performed by the Animal Use Subcommittee office. 
4.  Purchases of animals other than through this system must be cleared through the ACVS office. Health 
certificates will be required. 
 
ANIMALS APPROVED FOR 4 YEARS 
Species Strain Other Detail Pain 
Level 
Animal # Total 
for 4 years 
Rat Wistar 150-350 g C 680 
Pig Yorkshire-Landrace 50-60 kg B 30 
 
REQUIREMENTS/COMMENTS 
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar 
with the contents of this document. 
 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety components (biosafety, 
radiation safety, general laboratory safety) comply with institutional safety standards and have received all 
necessary approvals. Please consult directly with your institutional safety officers. 
 
 
 
 
 
 
 
c.c.  R Bihari, T Carter, K Bothwell, P Coakwell 
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